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INTRODUCTION
History of blood transfusion
Th e fi rst blood transfusion was prescribed during the Middle Ages, in 1492, to Pope 
Innocent VIII. Th e pope, as well as the three 10-year old boys who donated the blood, 
died during, or shortly aft er the procedure.1 Th roughout this period blood transfusion 
was freely recommended to remedy a variety of ailments, such as ill health, insanity, 
depressions, manias, but not for blood loss or anemia. Inevitably, transfusion to human 
beings led to more and more fatal side eff ects, thereby leading to its outlaw in many coun-
tries. For example, Pope Innocent XI banned blood transfusion in 1679 for the Catholics. 
In 1825, the London obstetrician James Blundell undertook the fi rst human-to-human 
transfusion to replace lost blood.2 Two important rules of Blundell remain important in 
clinical transfusion medicine today: 1) a human blood donor is only suited for a human 
recipient, and 2) blood transfusion is only indicated to compensate blood loss.2,3 Aft er 
the discovery of the erythrocyte blood groups, like the ABO blood group and the Rhesus 
blood group, the results of blood transfusions improved greatly.4-6 Despite the increasing 
utility of blood transfusion, it is interesting to note the relative lack of controlled clinical 
studies of transfusion of blood and derivatives until the last 10-15 years. Since the 1980’s, 
focus has been set on the appropriate clinical use and application of human blood and 
blood preparations and on the overall safety of transfusion.
Component therapy
At one time, all blood transfusions were collected and given as whole blood. During the 
1960’s component therapy became possible aft er introduction of the centrifugation tech-
nique. Whole blood units could then be divided into buff ycoats, used for the preparation 
of platelet concentrates, red blood cell (RBC) concentrates and plasma units. Th is chapter 
will focus on platelet and RBC transfusion.
Platelet transfusion
Platelet transfusions are indicated to control or prevent bleeding in patients with throm-
bocytopenia or platelet dysfunction. In particular, supportive and prophylactic platelet 
transfusions have reduced mortality and hemorrhagic complications in patients with 
acute leukemia.7-10 Th e recent surge in hematologic treatment options (e.g. stem cell 
transplantation) has lead to an increase in the use of platelet transfusions. However, time 
limited storage concerns and the ongoing need to recruit donors to maintain the fresh 
availability of the supply remain a worldwide challenge. Th is had led to increased eff orts 
in evidence based research on the collection, preservation and use of platelet concentrates 
to solve the logistic problems of the supply.
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RBC transfusion
Th e generally accepted reason for transfusing RBC is to increase the circulating RBC 
mass as a means to improve oxygen supply to the tissues.11 Patients with chronic and 
acute anemia are treated with RBC transfusions instead of whole blood to avoid the risk 
of circulatory overload.12,13 Despite the development of several techniques to reduce blood 
loss, RBC transfusion remains the cornerstone in the treatment of chronic and acute 
anemia. Th e easy availability and the seemingly safe use of blood and blood components 
in developed countries have even resulted in a liberal use of blood transfusions in clinical 
practice.
Transfusion triggers
Platelet transfusion
Th e threshold for prophylactic platelet transfusions is based on the platelet count of the 
patient (Table 1). Serious spontaneous hemorrhage in clinically stable patients may not 
occur with a platelet count of ≥ 10 × 109/L.14-19
Th e effi  cacy of platelet transfusions is diffi  cult to measure in routine clinical practice. 
Various methods have been investigated that predict in vivo survival from in vitro char-
acteristics. Th ese methods are of some value in the quality control of the platelet products, 
Table 1. Recommended platelet count in adults20
≥ 10 × 109/L Bone marrow depression by
− Leukemia
− Infi ltration tumor cells
− Drugs
− Chemotherapy
≥ 40 × 109/L − Before antithymocyte globulins
− During treatment with heparin (therapeutic) or Low-molecular weight heparin
− Gastroscopy, colonoscopy, rectumscopy, with or without biopsy
− Bronchoscopy without biopsy, with or without bronchoalveolar lavage
− Punction (ascites, pleural, and lumbar)
− Removing central-venous catheter
− Breathing
− Surgical interventions other than mentioned above
≥ 60 × 109/L − Biopsy (liver, renal, lung biopsy and biopsy during bronchoscopy)
− Tooth extraction
− Placement of central venous catheter (Hickman-, subclavian catheter, etc.)
− Sinus lavage in Ear-Nose-Throat area
≥ 100 × 109/L − Neurosurgery
− Cardio-pulmonary surgery
− Intracranial surgery
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but cannot predict in vivo survival. Th is is caused by patient factors as splenomegaly, 
alloimmunization, sepsis and disseminated intravascular coagulation. In vivo measure-
ment e.g. direct measurement of platelet survival with for example 51Cr or 111In, is not 
possible.21,22 Two indirect methods have been developed to assess the eff ect of platelet 
transfusion: the one hour Corrected Count Increment (CCI) and the platelet recovery 
method:
CCI =
Post- pre platelet count (× 109/L) × Body surface area of the patient (m2)
Number of platelets transfused (× 1011)
Recovery (%) = 100 ×
Absolute platelet increment (× 109/L) × Blood volume (L)
Number of platelets transfused (× 1011)
A CCI of >7.5 × 109/L at 1 hour and >2.5 × 109/L at 16-24 hours is considered successful.23 
A CCI of <7.5 × 109/L at 1 hour is likely to be due to an immunological cause. A normal 
1-hour CCI followed by a worse CCI aft er 16-24 hours may be due to a non-immuno-
logical cause. Th e recovery should theoretically be about 67% in a stable patient, but the 
minimum recovery to defi ne a successful transfusion is considered as >20% at 1 hour 
post transfusion and >10% at 20-24 hours. In clinical practice, the successfulness of a 
platelet transfusion is usually aff ected by several factors including damage to platelets in 
vitro and clinical variables in the patient.
RBC transfusion
As mentioned earlier, the generally accepted RBC transfusion goal is to increase the 
circulating RBC mass to improve oxygen delivery at the tissue level. To compensate for 
the reduced capacity of the blood to carry oxygen in a patient with chronic anemia the 
body reacts with 1) an increase in cardiac output, 2) a redistribution of blood fl ow and 3) 
an increase in the 2,3-DPG content of the red blood cells, which causes a shift  to the right 
in the oxygen dissociation curve, so that at a given degree of oxygen saturation of Hb, 
oxygen is more readily given up to the tissues.24,25 Clinically this process manifests in a 
variety of ways. Clinical symptoms of anemia are classifi ed as compensated (palpitations, 
dizziness, tachycardia), mild (weakness, sweating, tachycardia), moderate (restlessness, 
pallor, oliguria) and severe (collapse, air hunger, anuria) (Table 2).26,27
Friedman was the fi rst to introduce the term ‘transfusion trigger’, to describe the moment 
when blood transfusion is clinically indicated and should be prescribed.28 Although a 
Consensus Conference in 1988 emphasized the folly of relying on a single hemoglobin 
(Hb) value as an indication for transfusion, the Hb level currently remains the most im-
portant parameter in the decision to prescribe RBC transfusions.29-32 Th e most frequent 
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Hb transfusion trigger used is a Hb value of 5.0 mmol/l. Th is value is described in fi gure 1. 
Th is level is generally used as the cardiac output does not substantially increase until the 
Hb concentration falls to about 4.4 mmol/l. In addition, some authors suggest that Hb 
values below 5.0 mmol/l may lead to a worse haemostasis (e.g. a lower platelet adhesion 
capacity and a higher velocity).30,33-37 Th e possible risks of RBC transfusion, described in 
the next paragraph, have caused a reconsideration of transfusion policies in a number of 
clinical fi elds.38-40 Some authors have introduced a more restrictive transfusion policy by 
lowering the Hb transfusion trigger. In these studies no cardiovascular events occurred in 
stable patients when more restrictive transfusion trigger values were used.41-43 However, 
in elderly patients with acute myocardial infarction a higher Hb transfusion trigger of 6.0 
mmol/l is recommended.44
Recently, an international working group reviewed currently used response defi nitions 
of patients with chronic anemia (Myelodysplastic Syndromes (MDS)) and developed a 
uniform set of guidelines for future therapy and clinical trials.45 While RBC transfusions 
are the cornerstone in the treatment for MDS patients, treatment should be aimed at 
reduction of morbidity associated with cytopenias. Th e group especially emphasized the 
Figure 1. Hb dissociation curve
Table 2. Symptoms of blood loss27
Blood loss Blood pressure Symptoms and Signs Degree of shock
10% - 15%
(500 – 1000 mL)
Normal Palpitations, dizziness, 
tachycardia
Compensated
15% - 25%
(1000 – 1500 mL)
Slight fall Weakness, sweating, tachycardia Mild
25% - 35%
(1500 – 2000 mL)
70 – 80 mm Hg Restlessness, pallor, oliguria Moderate
35% - 45%
(2000 – 3000 mL)
50 – 70 mm Hg Collapse, air hunger, anuria Severe
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goal of improving the health related quality of life (HRQoL) of the blood transfusion 
recipients.
Health-related quality of life
Th e term HRQoL was introduced in the literature in 1967 for patients with chronic 
hemodialysis.46 Since that time, this subject has become more widely applied in clinical 
medicine, especially in patients with oncologic malignancies.
Th e HRQoL encompasses physical, psychological and social domains of health. Concep-
tually, HRQoL domains can be measured in terms of ‘objective’ functioning (what the 
patient is able to do) and, complementary, in the patients’ subjective evaluation thereof. 
HRQoL is measured using questionnaires. Generally, there are three types of HRQoL 
measures: 
1) generic measures, intended for use both in general population surveys and in studies 
of patients with diverse health conditions, allowing for comparison of HRQoL scores 
across disease stages and diagnostic groups; 
2) condition-specifi c measures, developed for use among specifi c patient population 
(e.g. cancer, diabetes); and 
3) domain-specifi c measures, for measurement of specifi c symptoms (e.g. fatigue, 
pain).
It is common practice to combine condition-specifi c and/or domain-specifi c measures 
with generic measures. Th e feasibility and other psychometric properties of HRQoL 
measures, however, may diff er between populations. 
HRQoL can only be partly explained by clinical variables.47 Still, patient-reported 
outcomes, including HRQoL, have increasingly been incorporated in the evaluation of 
medical interventions. For example, many physical diseases, in particular chronic dis-
eases such as cancer, multiple sclerosis, arthritis, renal disease, and HIV infection are as-
sociated with fatigue.48-52 Currently evidence supports the value of anemia management 
as a contributor to improving patient’s HRQoL by reducing fatigue in cancer patients 
receiving chemotherapy.53-57 However, the relationship between fatigue and diff erent Hb 
values has not yet been investigated.
Risks of blood transfusions
Since the nineties guidelines and directives from National and European health au-
thorities have required hospitals to institute a hemovigilance system. Th e objective of 
this hemovigilance system is to collect and assess information concerning unexpected 
and undesirable eff ects arising from the therapeutic use of labile blood products, and to 
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prevent the recurrence of such incidents. Results of the systems in France, the Nether-
lands (Transfusie Reacties In Patiënten; TRIP) and the UK (‘Serious Hazards Of Transfu-
sions’; SHOT) have shown a transfusion complication rate of 0.1 – 2.3 per 1000 blood 
products administered.58-60 Th e real incidence is probably higher because many incidents 
go unrecognized and/or unreported.
Complications of blood transfusions, however rare, can be divided into non-infectious 
and infectious complications. Non-infectious complications represent approximately 
99% of the reported incidents. Th ey can be divided into: 
1) incorrect blood component (‘wrong blood’) transfused; 
2) acute transfusion reaction; 
3) delayed transfusion reaction; 
4) transfusion-associated graft -versus-host-disease; 
5) transfusion-related acute lung injury (TRALI); 
6) post-transfusion purpura (thrombocytopenia arising 5-12 days following transfusion 
of RBC associated with the presence of antibodies directed against the HPA (Human 
Platelet Antigen) systems); and 
7) formation of RBC alloantibodies. 
Patients exposed to foreign antigens on platelets may develop alloantibodies that cause 
alloimmunization resulting in platelet refractoriness. Alloimmunization is most oft en 
due to patient antibodies against donor HLA class I antigens present on the leukocyte 
and platelet surface. Multitransfused patients have a risk varying from 12-22% to develop 
RBC alloantibodies.61-64 Various studies have showed that 17-30% of primary detected 
RBC alloantibodies were caused by RBC transfusion.65,66 Recently, the complication 
TRALI has become more prominent in clinical medicine.67 Increased understanding of 
the pathology and an enhanced awareness of this complication by physicians has signifi -
cantly increased the overall reporting of TRALI. Currently it is the third most reported 
transfusion complication.68
Infectious complications include transfusion-transmitted infections caused by bacterial, 
viral, prion, fungal, and parasitic infections. Although rare, infectious complications, 
especially bacteria-associated transfusion reactions, are identifi ed as the most frequent 
cause of death in transfusion incidents. Th e onset of symptoms related to a transfusion-
transmitted viral infection may occur from several weeks to years aft er the transfusion. 
Th e most common transfusion-associated viral infections include Human Immunode-
fi ciency Virus (HIV), Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C 
Virus (HCV), Human T-cell Lymphotropic Virus (HTLV), Cytomegalo Virus (CMV), 
Epstein Barr Virus (EBV), Parvovirus B19, and lately in the US West Nile Virus.69 For-
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tunately, the incidence of transfusion-related transmission of HIV, HBV and HCV has 
decreased signifi cantly aft er the introduction of several screening techniques (Figure 2). 
However, more recently, there has been a reported increase in parasitic infections like 
Trypanosoma Cruzi, especially in the southern states of the US and in Spain.70
Platelet transfusions and bacterial contamination
Currently the most frequent complication of platelet transfusion is bacterial contamina-
tion of the platelet products. Platelet concentrates are stored at room temperature for 
a maximum period of 5 to 7 days. Th ese conditions increase the risk of bacterial con-
tamination.72,73 Recently a photochemical treatment (PCT) process using the psoralen 
compound amotosalen HCL (S59) and long wavelength ultraviolet (UVA) light was de-
veloped for inactivation of infectious pathogens and leukocytes (Figure 3).74-76 PCT with 
S59 and UVA is a nucleic-acid-specifi c inactivation process with a broad spectrum of 
activity against bacteria, viruses, protozoa and leucocytes. S59 reversibly binds to DNA 
or RNA. By illumination, this binding becomes irreversible. Th us bacteria, viruses and 
protozoa are unable to replicate. Th e integral S59 Reduction Device (SRD) removes the 
residual S59 and free photoproducts.
Platelet components prepared with PCT off er the potential to further improve the safety 
of platelet transfusion using technology compatible with current buff y coat platelet com-
ponents preparation methods.77,78 However, for RBC transfusions pathogen inactivation 
techniques are not yet available for clinical use.
Figure 2. Risks of transfusion-related transmission of HIV, HBV and HCV in the USA71
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Scope of this thesis
Clinical blood transfusion practice is a lengthy, interrelated chain, from donor to recipient 
with diff erent links, which historically have improved at varying rates. Th e necessity of 
blood transfusion for chronically ill patients coupled with the grave potential for compli-
cation demands the introduction of more evidence-based studies in clinical transfusion 
medicine. Th is overview describes the application of evidence-based studies in clinical 
blood transfusion medicine. Improvement can be attained by the improvement of the 
actual blood and blood products as well as overall advancements in the practice of clini-
cal blood transfusions.
In chapter 2, a new technique to increase the safety of platelet concentrates, e.g. a 
photochemical treatment (PCT) for inactivation of infectious pathogens and WBCs, is 
introduced. Th e eff ect of PCT on the functional characteristics of the platelets was evalu-
ated in vitro. Chapter 3 compares the eff ects of a restrictive RBC transfusion therapy 
with those of a more liberal one for clinical patients treated with intensive chemotherapy 
for acute myeloid leukemia. Th is study was done retrospectively. Th erefore, the eff ect 
on the health-related quality of life (HRQoL) of the patients could not be measured. A 
cross-sectional pilot study performed for psychometric evaluation of three internation-
ally established HRQoL measures in patients with chronic anemia, and for investigation 
of the association between the severity of chronic anemia and HRQoL is described in 
chapter 4. Chapter 5 describes these HRQoL measures when evaluated in patients with 
acute anemia. Fatigue and HRQoL were investigated in women aft er vaginal delivery, 
Figure 3. Photochemical treatment technique
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elective, and emergency caesarean section (CS) and their relationship with postpartum 
Hb levels. Characteristics of these HRQoL measures in patients aft er delivery are shown 
in chapter 6. Finally, in chapter 7, the results are discussed, summarized and sugges-
tions for further research are made. A proposal for a new RBC transfusion model for 
patients with anemia is described. Special attention is given to the WOMB study. Th is is 
a prospective multicenter randomized clinical trial, which was developed to measure the 
role of RBC transfusion in the treatment of women with postpartum hemorrhage and 
the eff ects of RBC transfusion on HRQoL of this patient group. While this study is still 
ongoing, the design and some interim results are described in chapter 7.
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ABSTRACT
Background: A photochemical treatment (PCT) process using the psoralen compound 
amotosalen HCL (S59) and long wavelength UVA light was developed for inactivation of 
infectious pathogens and WBCs. In this study the eff ect of PCT on functional character-
istics of the platelets was evaluated in vitro.
Study design and methods: Platelet concentrates were treated photochemically using 
the experimental clinical processing system T-bag S59 Reduction Device (SRD) (n=4) or 
the commercially available integral processing system Wafer SRD (n=4) and compared 
with control platelet concentrates in plasma/PAS III alone (n=4). Th e evaluation included 
variables with respect to the overall quality of the product (e.g. HSR, pH), the function 
(aggregation and activation tests), apoptosis (annexin V and caspase 3), and lysis.
Results: No diff erences were found in the product quality variables, in P-selectin expres-
sion, and the apoptosis variables. PCT using the T-bag SRD led to a signifi cant decrease 
in aggregation capacity with collagen and thrombin and a signifi cant increase in plasma 
LDH, whereas no diff erences for the Wafer SRD were found.
Conclusion: PCT using the experimental T-bag SRD led to a signifi cant decrease in 
platelet function. However the commercially available Wafer SRD had only minor in 
vitro eff ects on the quality of the platelets.
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INTRODUCTION
Platelet concentrates (PCs) are predominantly used for the treatment of thrombocyto-
penic patients or patients with platelet dysfunction. Th ere are many controversies that 
surround platelet-transfusion practices today.1,2 Platelet transfusions are associated with 
a number of adverse events, like fever, bacteremia, exanthema and, rarely, GVHD.
A photochemical treatment (PCT) method, which utilizes the psoralen (S-59) and long 
wavelength ultraviolet light, has been developed to inactivate infectious pathogens and 
WBCs in PCs (Cerus Corporation, Concord, CA, and Baxter Healthcare Corporation, 
Deerfi eld, IL).3-6 A recent study of van Rhenen et al. assessed the application of PCT, using 
the experimental T-bag S59 Reduction Device (SRD), to platelets prepared from pooled 
buff y coats.7 Th e PCT process resulted in compatible in vitro overall quality variables of 
the PCs for up to 7 days of storage. However, PCT using the experimental T-bag SRD led 
to a signifi cant increase of lysis aft er 5 days of storage. Th e eff ect of PCT on functional 
characteristics of the platelets was not investigated.
In the current study, the eff ects of PCT platelets using the experimental T-bag SRD and 
the commercially available Wafer SRD on overall quality variables, apoptosis, lysis, and 
functional characteristics were compared to platelets in plasma/PAS III.
MATERIALS AND METHODS
Preparation of the buffy coats
Blood units of 500 ml ± 10 percent were collected from volunteer donors in 70 mL CPD 
anticoagulant solution using triple Optipac (Baxter Healthcare). Selection of donors 
and the blood-donation procedure were based on local standard practices. Th e whole 
blood units were kept overnight (16-20 hr) at room temperature (20 ± 2°C). High-speed 
centrifugation was applied to separate cellular components from plasma (Sorvall RC3C/
RC3bp Sorvall, Newtown, CT). Buff y coats (volume 55 ± 5 mL, Hct 0.50 ± 0.05 percent, 
and a rest volume of 3 mL plasma) were separated from plasma and RBCs using the 
Optipress II standard procedure.
Preparation of the pooled buffy coats
Using a sterile docking device SCD 312 (Terumo, Japan), 15 AB0-identical buff y coats 
were pooled in a 1.3-L PL 2410 plastic container. Aft er thorough mixing, the pool was 
divided into three equal volumes with the size of the pool set GURX 67b. To each of the 
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three pooling bags 280 ml PAS III (Intersol) was added to reduce the plasma concentra-
tion to 30 to 45 percent for optimal PCT performance.
Preparation of the leukoreduced buffy-coat derived PCs
Slow speed centrifugation (655 × g, 5 min) was applied to separate RBCs and WBCs from 
the fi ve buff y coat ABO Rh identical platelet-rich plasma-PAS III solution (Sorvall RC3). 
Leukoreduced PCs were prepared by manual fi ltration of the platelet-rich plasma-PAS III 
through a PLX 5 Asahi fi lter following standard blood-bank procedures. Th e control PC 
(Study Group 1) was stored in a fi nal PL 2410 1.3-L platelet storage bag.
Preparation of the PCT buffy-coat derived PCs
Using a sterile docking device TSCD (Terumo, Japan) two of the three leukoreduced PCs 
were docked to PCT train (GURX 68b). S59 was added to the PCs in a special (pl2410) 
illumination container. PCs were exposed to UVA (320-400 nm, 3 J/cm2) with constant 
agitation (60 cycles/min).
Th e S59-treated PCs were transferred to the S59 Reduction Device (SRD) to remove 
the excess of S59 and photo products from the PCs. Two diff erent SRD were used: the 
experimental clinical processing system T-bag SRD, which is used in previous in vitro 
and in vivo studies, 7,8 and the commercially available integral processing system Wafer 
SRD.9 Th e T-bag SRD contains 2.5 ± 0.1 g of absorptive beads enclosed in a polyester 
poach. Th e Wafer SRD is a solid-phase, waferlike structure with the same concentration 
of beads. Th e SRD treatment was done overnight for 16 hours at 20 ± 2°C with constant 
agitation (60 cycles/min) in a platelet storage climate cupboard.
Platelet storage
Aft er SRD treatment (Study Groups 2 and 3), the PCs were transferred into a fi nal 1.3-L 
PL2410 plastic bag. Th e PCs were stored for up to 11 days from collection, with constant 
agitation (60 cycles/min) at 20 ± 2°C in a platelet storage climate cupboard.
Day 0 was the day of collection, and Day 1 was the day of processing. Day 2 was the fi rst 
day of testing in this study.
Study groups
Because the products were pooled, a maximum of three diff erent pooled products was 
possible. Th e T-bag SRD was used experimentally and the new Wafer SRD is now com-
mercially available. PCT was only available in a PAS III/plasma solution. Th erefore, PC in 
PAS III/plasma functioned as control. Th e three study groups were 1) PC in plasma/PAS 
III; 2) PC in plasma/PAS III, PCT, 16-hour SRD using the experimental T-bag; and 3) PC 
in plasma/PAS III, PCT, 16-hour SRD using the commercially available Wafer.
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Overall quality variables
Platelet aliquots were drawn under sterile conditions on storage Day 2, 4, 7, 9 and 11. 
Haematological variables were measured electronically (Cell Dyn 3500, Abbott Labo-
ratories, Chicago, IL). Hct level, pH, pool volume, plasma volume, and volume of RBCs 
were measured starting on Day 2. Blood gases and bicarbonate were analyzed with a 
blood gas system (238 pH Blood Gas System, Ciba, Corning, UK).
Glucose concentration and lactate concentration were measured in a commercial ana-
lyzer (Dimension Chemistry Analyzer, Dupont, Wilmington, DE).
Functional characteristics
For estimation of platelet activation, P-selectin expression was measured by two-color 
labeling by fl ow cytometry (FACScan, Becton & Dickinson, San Jose, CA). FITC labeling 
of platelets was performed with anti-CD42a (Becton & Dickinson). P-selectin expression 
was determined using PE-labeled anti-CD62P (Becton & Dickinson).
Hypotonic shock response (HSR) was measured as described by Holme et al.9 Measure-
ments were performed on a spectrophotometer (LKB, Ultrospect II, Cambridge, UK).
Platelet aggregation was studied by aggregometry (Chrono-Log Whole Blood Aggrego-
meter 540 VS, Chrono-Log, Havertown, PA). Aggregation tests were performed on Day 
2, 4, 7, and 9. Platelet samples were diluted with Group 0 positive plasma to a platelet 
count of 200 × 109/L and incubated at room temperature for 2 hours before testing. 
Agonists were added to the samples to achieve fi nal concentrations as follows: ADP, 10 
μM; epinephrine, 0.1 μM; collagen 5 μg per mL; thrombin, 1 U per mL. ATP secretion 
was also measured according to the instructions of the manufacturer (Chrono-Log, 
Havertown, PA).
Apoptosis and lysis
Th e externalization of phosphatidylserine, which is a late result of apoptosis, was mea-
sured with Annexin V (BioVision, Kordia Life Sciences, Leiden, Th e Netherlands).11-13 
Caspase 3, a cysteinyl protease, plays a central role in the early apoptosis pathway. Its 
activity was measured with D2R (Alexis Biochemicals, Kordia Life Sciences, Leiden, Th e 
Netherlands).14 Apoptosis was measured on Day 2, 4, 7, 9, and 11. Diluted platelet sus-
pension (50 μL) were incubated with 5 μL of fl uorescein-labeled Annexin V or 1 μL D2R 
in the dark at room temperature.
Lysis was determined by measurement of the LDH concentration in the supernatant 
of the platelet suspension, using enzyme assay (Roche Diagnostics GmbH, Mannheim, 
Germany), following the standard procedure on Day 2, 4, 7, 9, and 11.
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Statistical analysis
All tests were performed in quadruplicate. In vitro data were expressed as the arithmetic 
mean ± SD. All data were analyzed paired T-test to determine signifi cant diff erences 
between the three groups of PC treatments. An alpha of 0.017 and a beta of 0.80 were 
used. Diff erences were considered signifi cant when p was less than 0.017. Because of 
the small sample size of four, detectable diff erences were 3 SDs or more. Analysis was 
performed in SPSS 10.0 for Windows.
RESULTS
Overall quality variables
No signifi cant diff erences were found for pool volume, Hct level, plasma volume and 
volume of RBCs (Table 1) between the three study arms. Platelet concentration was sig-
nifi cantly higher aft er PCT treatment using Wafer SRD compared to control platelets in 
plasma/PAS III, due to the higher plasma concentration aft er PCT treatment using Wafer 
SRD. No signifi cant diff erence in platelet concentration or loss over time was found when 
using PCT with the experimental T-bag SRD or the commercially available Wafer SRD 
(Table 2). All platelet products met the PCT target range requirements.7
Aft er PCT, platelets were compared to untreated control platelets during 7 days of stor-
age. No diff erences were found for pO2 or pCO2 between the three study arms. Although 
well maintained, pH and HCO3
- were signifi cantly lower aft er PCT. At Day 7, the pH 
in all groups was higher than 6.8, and the HCO3
- was higher than 4 mmol/L, providing 
adequate buff ering of the PCs. No signifi cant diff erences were found for glucose, lactate, 
ATP concentration, and HSR between the three study arms. A signifi cant but small in-
crease in mean platelet volume was found aft er PCT with the experimental T-bag SRD 
and the commercially available Wafer SRD (Table 2).
Table 1. Buffy-coat pool characteristics (mean ± SD)
Study arm Pool volume 
(mL)
Hct (L/L) Volume of 
RBCs (mL)
Platelet 
concentration 
(109/L)
Plasma 
volume (mL)
PAS III 563.7 (6.7) 0.57 (0.03) 147.4 (13.0) 304.3 (20.7) 136.3 (6.6)
PAS III, PCT,
T-bag SRD
562.0 (7.0) 0.57 (0.04) 139.8 (3.3) 315.1 (10.0) 142.4 (9.9)
PAS III, PCT, Wafer 
SRD
559.9 (3.7) 0.60 (0.01) 132.8 (2.3) 336.9 (4.2)* 147.1 (1.4)
*p<0.017 compared to PAS III, PCT, T-bag SRD
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Table 2. Overall quality variables 
Number Day 2
(mean ± SD)
Day 4
(mean ± SD)
Day 7
(mean ± SD)
Platelet concentration (x109/L)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
1302.3 ± 230.2
1254.5 ± 84.8
1330.5 ± 120.7
1260.5 ± 203.2
1223.5 ± 79.8**
1323.8 ± 101.0
1258.3 ± 223.0
1218.3 ± 80.7
1292.3 ± 87.7
PO2 (mm Hg)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
101.5 ± 15.0
98.5 ± 18.7
95.5 ± 22.0
69.3 ± 27.8
76.5 ± 3.9
63.5 ±7.9
77.3 ± 26.4
88.0 ± 5.1
75.8 ± 9.7
pCO2 (mm Hg)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
35.3 ± 5.7
35.3 ± 2.4**
39.8 ± 3.0
26.7 ± 4.0
25.8 ± 0.5
28.3 ± 1.7
23.5 ± 4.5
23.3 ± 0.5
26.0 ± 1.8
pH
PAS III (N=4)
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
7.06 ± 0.03
7.03 ± 0.01**
6.94 ± 0.06*
7.06 ± 0.05
7.06 ± 0.02**
6.97 ± 0.01*
7.0 ± 0.02
7.0 ± 0.01**
6.9 ± 0.01*
HCO3
- (mmol/L)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
10.1 ± 0.5
9.4 ± 0.3**
7.8 ± 0.1*
9.1 ± 1.0
8.9 ± 0.3**
7.3 ± 0.2
7.1 ± 0.4
7.1 ± 0.2
5.5 ± 0.2*
Glucose (mmol/L)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
8.0 ± 0.4
8.0 ± 0.3
7.8 ± 0.2
6.3± 0.4
6.4 ± 0.3
6.2 ± 0.2
2.7 ± 0.2
3.2 ± 0.4**
2.6 ± 0.3
Lactate (mmol/L)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
6.5 ± 0.8
5.9 ± 0.5
6.0 ± 0.6
9.9 ± 0.7
8.8 ± 0.6
8.9 ± 0.6*
16.1 ± 0.6
14.3 ± 0.6*
14.6 ± 0.5*
ATP (μmol/1011 platelets)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
3.1 ± 0.5
3.3 ± 0.8
3.5 ± 0.5
3.7 ± 0.6
3.3 ± 0.5
3.6 ± 0.4
2.8 ± 0.5
2.9 ± 0.3**
3.4 ± 0.5*
Hypotonic shock response (%)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
66.8 ± 4.0
65.0 ± 2.7
61.3 ± 4.9
61.5 ± 4.2
65.0 ± 1.4
63.3 ± 5.4
62.8 ± 3.3
66.3 ± 5.6
63.0 ± 2.9
Mean platelet volume (fL)
PAS III
PAS III, PCT, T-bag SRD
PAS III, PCT, Wafer SRD
4
4
4
7.4 ± 0.3
7.9 ± 0.4
7.8 ± 0.4
7.3 ± 0.3
7.9 ± 0.3
8.0 ± 0.1*
7.5 ± 0.5
8.0 ± 0.2**
8.3 ± 0.3*
*p<0.017 compared to PAS III
**p<0.017 compared to PAS III, PCT, Wafer SRD
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PCT platelets using the experimental T-bag SRD demonstrated signifi cantly less aggrega-
tion on Day 2 than control platelets with collagen as agonist. With thrombin as agonist, 
signifi cantly less aggregation was found on Day 4. Although not signifi cant, a decrease in 
aggregation was also seen for PCT platelets using the Wafer SRD. A signifi cant decrease of 
aggregation in time was seen in the three study groups for collagen and thrombin during 
storage. Th e ADP aggregation was strongly reduced for all groups starting from Day 2 (Fig. 
1A-C), which is according to earlier studies.10 No decrease was seen in ADP aggregation 
during storage of platelets, and no diff erences were seen between the three study groups.
Figure 1a. Collagen aggregation
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Figure 1b. Thrombin aggregation
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Activation
Th e P-selectin level started at 70 percent on Day 2 for the three study arms. Th ere was an 
increase of about 20 percent to a fi nal level of 90 percent on Day 11. PCT did not lead to a 
higher expression of the activation marker P-selectin. No diff erences were found between 
the three study groups (Table 3).
Apoptosis and lysis
No diff erences were found for annexin V expression between the three groups. On Day 2 
about 20 percent of the platelets were positive for annexin V. Th ere was a small increase in 
Figure 1c. ADP aggregation
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*p<0.017 PCT platelets using T-bag SRD compared to control platelets in plasma/PAS III. **p<0.017 
PCT platelets using Wafer SRD compared to PCT platelets using T-bag SRD. Aggregation percentages 
from fresh platelet rich plasma platelets isolated from venous blood above 50 percent considered normal. 
Table 3. Activation and apoptosis (mean percentage (SD))
Number Day 2 Day 4 Day 7 Day 9 Day 11
CD62 expression
PAS III
PAS III + T-bag SRD
PAS III + Wafer SRD
4
4
4
69.4 (10.6)
66.9 (8.4)
71.9 (5.9)
75.2 (8.5)
70.8 (5.2)
81.0 (2.1)
81.4 (2.1)
81.4 (1.2)
84.0 (4.3)
88.6 (2.3)
86.9 (2.4)
91.1 (1.9)
90.3 (4.0)
86.0 (4.0)*
91.3 (2.3)
Annexin V expression
PAS III
PAS III + T-bag SRD
PAS III + Wafer SRD
4
4
4
18.2 (7.2)
27.2 (11.7)
14.4 (2.5)
29.0 (4.0)
28.0 (13.9)
25.9 (5.9)
19.5 (4.8)
22.2 (11.8)
26.4 (3.1)
29.6 (1.3)
30.6 (6.9)
28.6 (11.8)
30.9 (15.0)
36.6 (0.14)
30.6 (3.0)
Caspase 3 expression
PAS III
PAS III + T-bag SRD
PAS III + Wafer SRD
4
4
4
1.15 (0.44)
1.28 (1.21)
0.78 (0.28)
2.18 (1.26)
2.20 (2.09)
1.78 (1.03)
3.67 (3.33)
2.18 (1.54)
3.63 (2.00)
3.73 (2.14)
2.43 (1.08)
2.83 (1.16)
3.13 (2.31)
1.48 (0.54)
1.53 (0.69)
*p<0.017 compared to PAS III, PCT, Wafer SRD
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time in all groups. A maximum of 4 percent of the platelets showed a possible caspase 3 ac-
tivity. Th ere might be a small increase during storage time. No signifi cant diff erences were 
found between the study arms. PCT did not lead to an increase in apoptosis (Table 3).
Th e LDH concentration was increasing over time. Th ere was a signifi cant diff erence 
between LDH concentration aft er PCT using the experimental T-bag SRD compared to 
control platelets. No diff erences were found between PCT platelets using the Wafer SRD 
and control platelets (Table 4).
DISCUSSION
In this in vitro study, functional characteristics of PCT platelets using the experimental 
T-bag SRD and the commercially available Wafer SRD were compared to control platelets 
in plasma/PAS III. No published data from platelets treated with PCT using the com-
mercially available Wafer SRD are yet available.
Control platelets in plasma/PAS III were characterized at the start (Day 2) by a better in 
vitro aggregation capacity than platelets treated with PCT using Wafer SRD and T-bag 
SRD, as shown by aggregation experiments with collagen and thrombin. Platelets treated 
with PCT using the commercially available Wafer SRD showed a slightly better in vitro 
aggregation capacity than platelets treated with PCT using the experimental T-bag SRD. 
In all three study groups, platelet function, as shown by aggregation experiments with 
collagen and thrombin, decreased over storage time. On average, PCT resulted in a loss 
of thrombin aggregation function of about 20 percent, compared to control platelets in 
plasma/PAS III. Several factors may account for this loss. To establish the cause of loss 
of function, we studied several variables that could contribute, such as overall quality 
variables, platelet activation, apoptosis, or lysis.
Table 4. LDH concentration (U/L, mean (SD))
Number Day 2 Day 4 Day 7 Day 9 Day 11
PAS III 4 200.8
(37.4)
270.5
(65.8)
318.8
(78.5)
508.3 
(302.3)
413.8 
(183.1)
PAS III, PCT, T-bag SRD 4 739.8 
(87.6)*
807.8 
(68.8)*
901.0
(89.0)*
878.8 
(163.6)
970.8 
(282.9)*
PAS III, PCT, Wafer SRD 4 276.3 
(61.6)**
411.0 
(208.1)
509.0 
(391.7)
316.0
(36.6)**
330.3
(47.8)**
*p<0.017 compared to PAS III
**p<0.017 compared to PAS III, PCT, T-bag SRD
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All three platelet products met the PCT target range requirements for the overall quality 
variables. PCT seems to have only a minor eff ect on overall quality variables.
For platelet activation, the expression of P-selectin, which is a marker of release of α-
granules, was measured. Th e expression of P-selectin was comparable for these study 
groups. PCT had no additional eff ect on activation of platelets as shown with CD62 ex-
pression. Expression of CD62 is infl uenced by magnesium and potassium and is higher in 
PCs with PAS/plasma solution than PCs in plasma only (unpublished results).14 Because 
in an earlier clinical study no diff erences in count increment aft er platelet transfusion 
were observed, P-selectin expression might be a reversible characteristic of PC in a PAS 
solution.9 However, there have been confl icting data regarding the role of P-selectin in 
in-vivo outcomes.15-18
Apoptosis is a major form of cell death, characterized initially by a subset of stereotypic 
morphological changes.19 Caspases, which are cysteinyl proteases that cleave aft er aspar-
tic acid, are key eff ectors of apoptosis. Caspase 3 plays a central role in the early apoptosis 
pathway, 13,20,21 which leads to the externalization of phosphatidylserine to the surface of 
the platelet membrane, detectable with annexin V.10-12 In this study, no additional eff ect 
on caspase 3 activity and annexin V expression was found. Annexin V is also detect-
able when platelets are activated. Th erefore, the role of apoptosis (markers) in platelets 
remains unclear.
Th e increased lysis of platelets, as measured by plasma LDH, using the T-bag SRD com-
pared to the commercially available Wafer SRD, suggests that the T-bag SRD is more 
harmful to platelets than the Wafer SRD, probably due to mechanical cause. Th e decrease 
in platelet function aft er PCT, shown by the aggregation experiments, was more pro-
nounced for T-bag SRD than for Wafer SRD, which might be explained by the signifi cant 
higher percentage of lysis.
In two recently performed clinical studies, platelets treated with PCT using T-bag SRD 
showed diff erent results on the 1-hour and 24-hour CCI compared to control platelets 
treated in plasma/PAS II.8,22 Th e sample size of our in vitro study was small, which in-
creases the risk of Type II errors. However, even if beta-type errors were inadvertently 
made due to the small sample size, the results of our in vitro study are in agreement with 
the clinical performance of the PCT platelets in the in vivo study and suggest that PCs 
aft er PCT using Wafer SRD are less harmful to platelets than T-bag SRD.
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ABSTRACT
Background: Red-cell transfusions are required for symptomatic treatment of severe 
anemia caused by intensive chemotherapy. Concerns about the transfusion-related 
complications, such as infections (e.g. the very low risk of human immunodefi ciency 
virus (HIV)/hepatitis C (HCV) transmission and the risk of postoperative infections), 
hemolytic transfusion reaction, immunological eff ects and the costs, prompt a reevalua-
tion of the transfusion practice.
Study design and methods: Retrospective analysis of prospectively collected data on 
84 patients with acute myeloid leukemia (AML), who were treated with combination 
chemotherapy between June 1, 1997 and December 7, 2001, was performed. Th e use of 
red-cell transfusions with a restrictive transfusion policy (hemoglobin = 7.2-8.8 g dL-1, 
dependent on age and symptoms, n=38) was compared with a more liberal transfusion 
trigger (hemoglobin = 9.6 g dL-1, n=46). Th e number of units transfused was recorded. 
Signs and symptoms of anemia, chemotherapy-related eff ects and complications were 
investigated for both transfusion policies.
Results: Th e more restrictive transfusion policy led to a signifi cant decrease of 11% of red 
blood cell transfusions in patients with AML. No signifi cant diff erences were found in 
the incidence of infections, number of platelet units transfused, bleeding complications, 
cardiac symptoms or response to chemotherapy. 
Conclusion: Th e more restrictive transfusion policy was feasible in this clinical setting 
and it might be concluded that a restrictive transfusion policy is safe in supporting clini-
cal patients treated with intensive chemotherapy for AML.
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INTRODUCTION
Pancytopenia is a common complication of myelosuppressive chemotherapy. Allogeneic 
red blood cell (RBC) transfusions are required for symptomatic treatment of the severe 
anemia caused by intensive chemotherapy.1 Th e transfusion requirement is infl uenced 
by diff erent clinical factors, of which the kind of chemotherapy is the most important 
one.2 Other clinical events include tumor burden, fever, bacteriaemia, systemic fungal 
infection, mucosal bleeding, melaena/haematemesis and diarrhea. Th e effi  cacy of trans-
fusional support seems to decrease gradually during the cytopenic period.2-4
Most clinical practice guidelines recommend a restrictive allogeneic RBC transfusion 
practice in patients without cardiac complications in the surgical and medical intensive 
care unit.5-8 However, the optimal transfusion trigger in the hematological intensive 
care unit has not been defi ned and oft en diff ers between hospitals.4 A hemoglobin (Hb) 
concentration of below 9.6 g dL-1 is generally taken as a trigger for RBC transfusion in 
hematological patients with a pancytopenia.9 Concerns about transfusion-related com-
plications, such as the risk of human immunodefi ciency virus (HIV)/hepatitis C (HCV) 
transmission or postoperative infections, tumor behavior and immunological complica-
tions, as well as rising costs, led us to reconsider the transfusion policy. To assess a restric-
tive transfusion policy in hematological patients treated with intensive chemotherapy, 
new guidelines for the administration of red cells were introduced. Th e objective of this 
study was to investigate to what extent a restrictive transfusion policy decreases the total 
number of RBC transfusions and the number of units given per transfusion. In addition, 
clinical events associated with pancytopenia in both the restrictive transfusion policy 
and the liberal transfusion policy were compared. Th e University Hospital, Rotterdam, 
has a Hematology department split between two sites in Rotterdam. In both sites, the 
same prospective HOVON 29 study was going on. Th e only diff erence between the two 
sites was the transfusion trigger for RBC transfusion. Th e site determined whether the 
patient was allocated to the restrictive or the liberal transfusion group.
MATERIAL AND METHODS
Patients
In this retrospective study, data were analyzed which were collected prospectively 
according to the Good Clinical Practice directives of HOVON leukemia protocols at 
the intensive care unit of the department of Hematology, Erasmus Medical Center 
Rotterdam. Patients in the Erasmus Medical Center (central location) were transfused 
according the restrictive policy, whereas the liberal transfusion strategy was applied in 
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the other location (Daniel den Hoed Kliniek). From June 1, 1997 to December 7, 2001 
84 patients with newly diagnosed acute myeloid leukemia (AML), who were between 15 
and 60 years of age, were treated with combination chemotherapy (ARA-C 200 mg m-2 
on days 0-6 and Idarubicin 12 mg m-2 on days 1-3). Th e AML was classifi ed according the 
French-American-British (FAB) classifi cation. A poor, good, or intermediate risk clas-
sifi cation as defi ned by the HOVON leukemia protocol was used: Good risk = AML with 
t(8;21)(q22;q22) or AML1/ETO fusion gene and white blood cell (WBC) ≤ 20x109/l at di-
agnosis and no additional unfavorable cytogenetic abnormalities or inv/del(16)(p13;q22) 
or MYH11/CBFβ fusion gene and no additional unfavorable cytogenetic abnormalities 
(more than three distinct clonal abnormalities; monosomes of chromosomes 5 or 7; del 
5q or del 7q; abnormalities of the long arm of chromosome 3; t(6;9)(q23;q34) or DEK-
CAN fusion gene; abnormalities of the long arm of chromosome 11). Intermediate risk = 
AML patients not assigned to Good risk or Poor risk. Poor risk = AML with unfavorable 
cytogenetic abnormalities, except those with simultaneous favorable cytogenetic abnor-
malities. In this study the transfusion requirements of these patients were studied under 
the two transfusion policies during the fi rst induction cycle of chemotherapy.
Transfusion regimens
All patients received leukocyte-depleted RBC concentrates with a leukocyte count of less 
than 1x106 L-1. RBCs were suspended in a 110 ml SAG-M solution, with a haematocrit of 
0.60 to a total volume of 265 mL.
Restrictive transfusion policy
In the revised restrictive transfusion protocol, age dependent lower limits were applied 
for prophylactic transfusion (Table 1). Patients younger than 25 years of age received a 
RBC transfusion when their Hb level dropped below 7.2 g dL-1. In patients between 25 
and 50 years of age, a transfusion trigger of below 8.0 g dL-1 was used. In patients between 
50 and 70 years of age, the hemoglobin threshold was below 8.8 g dL-1. RBC transfusions 
were administered on a unit-by-unit basis.
Liberal transfusion policy
Th e liberal transfusion policy was the standard practice at the start of the study. According to 
the liberal protocol, RBC transfusions were given when the hemoglobin level dropped below 
9.6 g dL-1 (Table 1). Two units were given per transfusion in the liberal transfusion policy.
RBC transfusions were always given regardless of the hemoglobin concentration, if signs 
and symptoms of a decreased oxygen transportation capacity such as dyspnoea, syncope, 
postural hypotension, tachycardia (>100 bpm), angina pectoris or transient ischemic 
attack (TIA) occurred.
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Clinical outcomes
Clinical outcomes like mortality, hemorrhages, infections, cardiac dysrhythmias and 
cardiac dysfunction (WHO-CTC grade 2 or higher), response to chemotherapy and 
myeloid: erythroid (M:E) ratio of the bone marrow smears were recorded.
Statistical methods
Statistical analysis was performed in SPSS for Windows 8.0. Frequencies were described 
as mean, median, range, standard error of the mean and SDs. Diff erences between the 
groups in the number of RBC transfusions and the total number of units of RBC given 
per transfusion were analyzed with the nonparametric Mann-Whitney test. To allow for 
potential confounding factors (sex, age and AML type) multiple regression was used aft er 
logarithmic transformation of the total number of RBC transfusions (e.g. the primary 
outcome). Diff erences between the total number of platelet transfusions and the number 
of units of platelets given per transfusion were also analyzed with the nonparametric 
Mann-Whitney test. Diff erences between complication rates were tested using the χ2 test. 
P values < 0.05 were considered statistically signifi cant.
RESULTS
Th e restrictive group consisted of 38 patients and the liberal group of 46 patients. Th ere 
were no signifi cant diff erences between these two groups in sex distribution, age, FAB 
classifi cation, or risk classifi cation. Th e mean follow-up period was 30 days for the re-
strictive group and 32 days for the liberal group (all P > 0.05). Characteristics of the two 
patient groups are shown in Table 2.
Table 1. Transfusion policies.
Age (Years) Restrictive group Liberal group
Hb transfusion 
trigger (g dL-1)
Mean Hb
(g dL-1)
Hb transfusion 
trigger (g dL-1)
Mean Hb
(g dL-1)
<25 7.2 7.5 (n=3) 9.6 8.8 (n=3)
25-50 8.0 8.0 (n=22) 9.6 9.3 (n=32)
50-70 8.8 8.3 (n=13) 9.6 9.5 (n=11)
Total 8.2 8.0 (n=38) 9.6 9.3 (n=46)
The Hb transfusion triggers for the restrictive group and the liberal transfusion group. The Hb column 
is the Hb guideline for both policies and the mean Hb column shows the mean Hb values during the 
follow-up period. There is a signifi cant difference between the transfusion groups in the mean Hb value 
(p<0.05).
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Table 2. Patient characteristics
Variables Restrictive group (n=38) Liberal group (n=46) Total (n=84)
Sex
Male
Female
18
20
21
25
39
45
Age (Years) + SD 43.2 (11.7) 42.5 (10.5) 42.8 (11.0)
FAB-classifi cation
M0
M1
M2
M3
M4
M5
M6
2
11
9
3
9
2
1
2
11
11
5
4
13
0
4
22
20
8
13
15
1
Risk classifi cation*
Good risk
Intermediate risk
Poor risk
Unknown
7
19
11
1
6
28
10
2
13
47
21
3
Social demographic variables and French-American-British (FAB) classifi cation of the acute myeloid 
leukemia (AML) patients. There are no signifi cant differences between the restrictive group and the liberal 
group (p>0.05) for sex, age, FAB classifi cation and risk classifi cation.
Table 3. Overview of erythrocyte and platelet transfusions
Total number 
of RBC 
transfusions
Number of RBC 
units given per 
transfusion
Total number 
of platelet 
transfusions
Number of platelet 
units given per 
transfusion
Restrictive group
Mean
Median
SD
St. error of the 
mean
Range
9.6
9.0
3.9
0.6
3.0 – 21.0
1.3
1.0
0.5
0.03
1.0 – 4.0
7.5
7.0
3.8
0.6
2.0 – 18.0
1.1
1.0
0.4
0.03
1.0 – 4.0
Liberal group
Mean
Median
Std. deviation
St. error of the 
mean
Range
10.8
11.0
2.9
0.4
6.0 – 21.0
1.8
2.0
0.4
0.03
1.0 – 5.0
8.5
7.0
4.9
0.7
2.0 - 30.0
1.2
1.0
0.5
0.03
1.0 - 4.0
Overview of the number of RBC transfusions and the number of units of RBC given per transfusion 
in the fi rst 31 days after starting chemotherapy. There are signifi cant differences (p<0.05) between 
both groups in the total number of red blood cell (RBC) transfusions and in the total number of units of 
RBC given per transfusion in favor of the restrictive transfusion policy. In the total number of platelet 
transfusions and the number of units of platelets given per transfusion, there were no differences 
between the two transfusion groups.
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Mean hemoglobin values during the follow-up period are shown in Table 1. Guidelines 
of both the restrictive and the liberal transfusion policy were followed correctly. A 
signifi cant diff erence was found between the groups of 1.3 gdL-1 in the mean Hb value 
(P < 0.05) during the follow-up period. Th e total number of RBC transfusions and the 
average number of RBC units given per transfusion are shown for both groups in Table 3. 
Th e restrictive group received on average 9.6 (± 3.9) RBC transfusions, the liberal group 
received 10.8 (± 2.9) RBC transfusions, a signifi cant diff erence of 11 percent (P = 0.05). 
Th e unadjusted ratio of geometric means was 1.17 and the 95% confi dence interval (CI) 
ranged from 1.01 to 1.37. Adjusted for age, sex and AML type, the diff erence remained 
signifi cant (1.25, P = 0.007) and the 95% CI for the ratio of adjusted geometric means 
ranged from 1.07 to 1.47. Per transfusion a mean of 1.32 (± 0.5) units of RBC were given 
in the restrictive group as compared to 1.82 (± 0.4) units in the liberal group (P < 0.05). 
Th e mean interval between RBC transfusions was 3.1 days in the restrictive group and 
3.0 days in the liberal group.
Th ere were no signifi cant diff erences in the total number of platelet transfusions and 
the number of platelet units given per transfusion (Table 3). Th e mean interval between 
platelet transfusions in the restrictive group was 4.0 days and 3.8 days in the liberal 
group. Th e incidence of bleeding complications (CTC grade 2 or more) was not diff erent 
(3/38 patients in the restrictive group, 8/46 patients in the liberal group with 1 or more 
bleeding complications, P = 0.24).
Table 4. Cardiac events
Cardiac Rhythm 
dysfunction
95% Confi dence 
Interval
Cardiac Function 95% Confi dence 
Interval
Restrictive Group (N=38) 1/38 0.1% - 14% 3/38 0.6% - 18%
Liberal Group (N=46) 1/46 0.1% - 12% 5/46 4% - 24%
Overview of the cardiac events WHO-CTC grade 2 or more. No differences were found for cardiac 
dysrhythmias and cardiac dysfunction (p>0.05).
Table 5. Therapy response 
Restrictive group n (%) Liberal group n (%)
Complete Remission 22 (58) 27 (59)
Partial Remission 7 (18) 11 (24)
No Response 7 (18) 7 (15)
Mortality 1 (3) 1 (2)
Relapse extramedullary leukemia 1 (3) 0
Total 38 (100) 46 (100)
Overview of the therapy response in the restrictive transfusion group and the liberal transfusion group. No 
signifi cant differences were found in therapy response.
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Diff erences between both groups for cardiac complications, e.g. episodes of cardiac ar-
rhythmia and cardiac dysfunction, were not signifi cant (Table 4). No diff erences were 
found in incidence of infections and type of infective agents.
Th e measured bone marrow M:E ratios were similar between the groups. Also, no 
signifi cant diff erences were found in therapy response, e.g. complete remission, partial 
remission, no remission or death, between the restrictive group and the liberal group 
(Table 5). 
DISCUSSION
Allogeneic RBC transfusions will always carry some inherent risks in terms of infections 
and immunomodulatory eff ects. Th e limited published evidence supports the use of 
restrictive transfusion triggers in patients without cardiac risk factors and symptoms.5,7 
In the hematological intensive care, a liberal transfusion trigger of 9.6 g dL-1 is common 
practice. Th is trigger is mostly based on literature of systematic reviews and oft en diff ers 
between hospitals.4 It is the question whether this literature is relevant for AML patients, 
who are sick but not very old. In this retrospective analysis of prospectively collected 
data, a newly developed restrictive transfusion trigger protocol was studied. Th is new re-
strictive transfusion policy appeared to be feasible in this clinical setting as the guidelines 
were followed correctly (Table 1).
Th e new policy led to a signifi cant decrease in the use of allogeneic RBC transfusions for 
patients treated with chemotherapy for AML. No diff erences were found in the incidence 
of cardiac complications, so it may be concluded that the restrictive transfusion trigger is 
also safe in hematological intensive care.
Anemia might induce prolonged bleeding time (BT), especially in thrombocytopenic pa-
tients.10 It has been suggested that RBC transfusion might decrease the activated partial 
thromboplastin time and the BT in some anemic patients, which would reduce the risk of 
hemorrhage complications.11,12 However, in this study, a reduction of bleeding complica-
tions was found in the patient group with the restrictive transfusion trigger. Th is result is 
supported by a decreased use of platelet transfusions in this group. Further clinical trials 
are needed to investigate this eff ect of RBC transfusions on bleeding complications in 
patients with a hematological malignancy.
Decreased hemoglobin levels in anemic cancer patients usually lead to a reduction of 
physical fi tness and impaired Health Related Quality of Life (HRQoL). Consideration of 
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treatment of mild-to-moderate anemia will probably become more important as greater 
emphasis is placed on HRQoL in the management of hemato-oncological patients. For 
the development of more eff ective therapeutic interventions based on outcomes such 
as HRQoL as well as hemoglobin levels, further research into the relationships between 
hemoglobin levels, patients’ well-being and safety and symptoms is needed. A restrictive 
transfusion policy, of which the feasibility has been demonstrated in this study, is the fi rst 
step in this development.
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ABSTRACT
Background: Th e myelodysplastic syndromes (MDS) are clonal disorders characterized 
by dysplasia in at least two myeloid cell lines. Fatigue is one of the most signifi cant symp-
toms. MDS patients are treated with blood transfusions to improve their health-related 
quality of life (HRQoL).
Study design and methods: A cross-sectional pilot study was performed for psychomet-
ric evaluation of three internationally established HRQoL measures in MDS patients, and 
for investigation of the association between the severity of chronic anemia and HRQoL. 
Fift y consecutive MDS patients completed the Short Form 36, the Multidimensional 
Fatigue Inventory and the EuroQoL-5D Visual Analogue Scale. Hb level was measured 
during the same visit. Psychometric analysis focused on feasibility, construct validity and 
reliability.
Results: Th e questionnaires showed a high feasibility, reliability and validity. MDS pa-
tients had worse HRQoL scores than the age- and sex-matched general population. We 
found a positive correlation between hemoglobin (Hb) level and HRQoL.
Conclusion: Th is study provides insights into the suitability of established HRQoL 
measures for the evaluation of interventions in MDS patients. Hb value and HRQoL are 
complementary variables for evaluation of the severity of chronic anemia in patients with 
MDS.
51
Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
INTRODUCTION
Th e myelodysplastic syndromes (MDS) are characterized by peripheral blood cytopenia 
with hypercellular bone marrow and dysplasia of the cellular elements.1 Patients with 
MDS make up a heterogeneous population, with clinical features ranging from mild, 
stable cytopenia to severe pancytopenia with life-threatening symptoms and a high risk 
of progression to acute myeloid leukemia (AML). Th e most important clinical feature is 
chronic anemia, with fatigue as the most important symptom.2 Th is fatigue is not an iso-
lated physical symptom but rather involves lethargy, decreased mental alertness, physical 
weakness and poor concentration.
Recently, an international working group reviewed currently used response defi nitions 
of MDS, and developed a uniform set of guidelines for future therapy and clinical trials.3 
Treatment should aim to reduce the morbidity associated with cytopenias and, espe-
cially, to improve the health-related quality of life (HRQoL). Red cell transfusions are 
the cornerstone of the treatment for MDS patients. Although improving HRQoL is the 
major goal of blood transfusion, the HRQoL of MDS patients has not been investigated 
empirically.
In general, fatigue has the most important impact on the HRQoL of the individual in 
cancer patients before, during and aft er treatment.4,5 Th e impact of MDS on HRQoL 
can be far reaching: in addition to the physical symptoms (e.g. bleeding and infection), 
fatigue, uncertainty, lack of understanding of the disease process, fear of conversion to 
acute myeloid leukemia and lack of communication with clinicians may infl uence the 
HRQoL.6 HRQoL is subject to change over time in response to the course of the ill-
ness and/or treatment. A pilotstudy was conducted in MDS patients, which included 
the psychometric evaluation of three internationally established HRQoL methods, and 
investigation of the association between the severity of chronic anemia and the HRQoL.
MATERIAL AND METHODS
HRQoL covers physical, psychological and social issues (domains). Conceptually, 
HRQoL domains can be measured in terms of ‘objective’ functioning (what the patient 
is able to do) and the complementary subjective evaluation by the patient. Th e present 
study included both objective and subjective elements. It is common practice to combine 
generic measures, allowing for comparison of HRQoL scores across disease stages and 
diagnostic groups, with condition-specifi c and/or domain-specifi c measures.
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Fift y consecutive MDS patients from three general hospitals and one university hospital 
completed a questionnaire consisting of the Short Form 36 (SF-36, generic HRQoL mea-
sure), the domain-specifi c Multidimensional Fatigue Inventory (MFI) and the EuroQoL-
5D Visual Analogue Scale (VAS) for self-related health within 24 h of a regular visit to 
the outpatient clinic. Th e hemoglobin (Hb) level was measured at the outpatient visit 
and no blood transfusions were given for 24 h aft er this appointment. Th e patients were 
classifi ed following the French-American-British (FAB) classifi cation for MDS.
Based on the results of a psychometric analysis of four generic health measures in mi-
graine patients, the SF-36 appeared to be the most suitable generic measure for describing 
HRQoL in that group of patients.7 Th e SF-36, developed in the USA, is derived from the 
larger battery of health status instruments employed in the Medical Outcomes Study.8-11 
It consists of 36 items, organized into eight scales: mental health, physical functioning, 
role physical, role emotional, social functioning, bodily pain, general health perceptions 
and vitality. Th e number of response choices per item ranges from two to six. Th e SF-
36 yields an eight-dimensional profi le, with each scale having a range from 0 to 100 
(100=optimal).
Th e SF-36 furthermore provides a physical sum score (PCS; predominantly based on the 
scales physical functioning, role physical, bodily pain and general health perceptions) 
and a mental sum score (MCS; e.g. scales mental health, role emotional, social function-
ing and vitality) (range 0-100, 100 = optimal).12 PCS and MCS are constructed so that 
the general US population had a mean score of 50 and a standard deviation of 10. Th e 
Dutch version of the SF-36 employed in the current study was developed as a part of 
the International Quality of Life Assessment (IQOLA) Project, the objective of which 
is to translate, validate and norm the SF-36 in a wide range of languages and cultural 
settings.
Th e EuroQoL VAS, the sixth item of the generic EQ-5D measure, is a global evaluation of 
“own health today” using a visual analogue scale ranging from 0 (worst imaginable health 
state) to 100 (best imaginable health state).13
Th e Multidimensional Fatigue Inventory (MFI) was chosen to measure fatigue, the most 
important complaint of MDS patients. It was developed as a tool to assess fatigue in a 
comprehensive way, with a special interest in fatigue as experienced by patients. Th e MFI 
is a 20-item self-report instrument designed to measure fatigue in cancer and non-cancer 
patients.14,15 Th e questionnaire covers fi ve diff erent dimensions: general fatigue, physical 
fatigue, mental fatigue, reduced motivation and reduced activity. Th ere are four response 
choices per item. Each scale has a range from 4 to 20 (4=optimal).
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STATISTICS
Feasibility
Th e number of missing cases per item was employed as an empirical indicator of feasibil-
ity. Missing values were defi ned as those cases where no answer was provided and those 
where multiple responses were given, when only one was required. For VAS and MFI no 
constructed values for missing values were imputed. For the SF-36, constructed values 
for missing values were imputed following guidelines in the manual. Completion time 
was defi ned as the time required for the patients to complete the questionnaire.
Score distribution
Mean scores, standard deviations, and the percentages of respondents with the maxi-
mum possible score and the minimum possible score, respectively, were computed per 
scale.14,16 For SF-36, mental and physical sum scores were calculated.12
Reliability
Th e internal consistency of the SF-36 and the MFI multi-item scales was determined with 
Cronbach’s alpha-coeffi  cient. An alpha-coeffi  cient of 0.70 or higher was considered as 
suffi  cient for the purpose of group comparisons. Owing to the cross-sectional nature of 
the study, data on test-retest reliability were not available.
Correlation HRQoL and hemoglobin level
Th e eff ects of various factors on HRQoL (MDS subtype, hospital, sex and age), in addition 
to Hb level, were investigated using multiple regression analysis. Th e correlation between 
Hb level and HRQoL was analyzed using the Spearman’s correlation coeffi  cient.
Effect size
Eff ect size (ES) is a name given to a family of indices that measure the magnitude of a 
treatment eff ect. To measure the eff ect of Hb level on HRQoL, patients were divided 
into two groups by median Hb level (e.g. lower or higher than 9.5 g/dL). Cohen’s d is 
defi ned as the diff erence between the means, divided by standard deviation, sigma, of 
either group. Following Cohen’s suggested guidelines, d=0.2 was taken to indicate a small 
eff ect size, d=0.5 a moderate eff ect size and d=0.8 a large eff ect size.17
P-values < 0.05 were considered signifi cant. All statistical analyses were performed the 
SPSS package, version 10.0, for Windows. 
Chapter 4
54
RESULTS
Between July 2001 and December 2001, 50 patients were enrolled; their characteristics 
are summarized in Table 1. Th ere were no diff erences in Hb level and age between the 
hospitals, sex and MDS subtype respectively (P > 0.05).
Feasibility
Th e median completion time of the questionnaire was 15 min (range: 8-60 min). Fift een 
patients needed help with completing the forms. One patient fi lled in only VAS and SF-
36 (no MFI). One patient did not complete all MFI items, one patient did not fi ll in MFI 
subscale general fatigue and two patients did not complete MFI subscale reduced activity. 
Two patients did not complete the SF-36 subscales role physical and role emotional.
Score distribution
Th e scores of VAS, SF-36 and MFI were well distributed within the recorded ranges. 
Th e median scores of VAS, SF-36 and MFI of the MDS patients were lower than the 
median scores of subjects from the Dutch general population of similar age and sex.4,14,18 
In particular, the scores on the physical domain of the HRQoL were worse, e.g. physical 
functioning, role physical and physical sum score (SF-36) and physical fatigue (MFI).
Reliability
Th e internal consistency coeffi  cients for the MFI and the SF-36 are shown in Table 2. All 
MFI had alpha-coeffi  cients greater than 0.80. Six of the eight SF-36 had alpha-coeffi  cients 
greater than 0.80.
Table 1. Characteristics of the 50 patients
Characteristics Value
Sex (M/F) 31 / 19
Age (years)
Median
Range
73
49 – 93
Hb (g/dL)
Mean
Range
9.7
6.6 – 16.6
MDS subtype (N)
RA
RARS
RAEB
RAEB-t
CMMoL
14
13
15
1
5
RA, refractory anemia; RARS, RA with ringed sideroblaststs; RAEB, RA with excess blasts; RAEB-t, RAEB 
in transformation; CMMoL, chronic myelomonocytic leukemia.
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Table 2. Descriptive statistics of VAS, SF-36 and MFI: Spearman’s correlation coeffi cient (Rs) p values 
and effect size (d) for a relationship with Hb
Worst 
(%)d
Best 
(%)d
Mean
(SD)
Cronbach’s 
alpha
Rs
e p df
VASa (score 0-100) 2 2 61.2
(18.4)
0.29 0.05 0.47**
MFIb (score 4-20)
General Fatigue 17 4 13.2
(4.9)
0.94 -0.11 0.46 0.10*
Physical Fatigue 14 6 13.6
(4.4)
0.88 -0.31 0.03 0.48**
Mental Fatigue 2 25 8.4
(4.2)
0.82 -0.26 0.07 0.43**
Reduced Activity 15 4 13.1
(4.5)
0.83 -0.34 0.02 0.77**
Reduced Motivation 6 6 12.0
(4.7)
0.81 -0.27 0.06 0.43**
SF-36c (score 0-100)
Bodily Pain 2 42 66.6
(31.2)
0.83 0.08 0.58 0.20*
General Health 2 2 41.5
(21.3)
0.75 0.15 0.29 0.14*
Mental Health 2 8 72.3
(20.9)
0.84 0.09 0.52 0.18*
Physical Functioning 4 2 48.1
(30.6)
0.94 0.50 0.00 0.73**
Role Emotional 23 44 59.0
(41.4)
0.79 0.22 0.13 0.14*
Role Physical 44 27 39.2
(42.5)
0.89 0.35 0.02 0.35**
Social Functioning 6 20 67.0
(29.6)
0.80 0.18 0.22 0.08*
Vitality 2 2 50.6
(25.3)
0.86 0.33 0.02 0.51**
Physical sum score 2 2 35.7
(11.7)
0.35 0.01 0.48**
Mental sum score 2 2 48.9
(12.6)
0.09 0.54 0.07*
aVAS scores ranged from 0 to 100 (100= best). The mean score of healthy age- and sex-matched 
control subjects was 80; bMFI subscales ranged form 4 to 20 (4=best, 20=worst); cSubscales of SF-36 
scores ranged from 0 to 100 (100= best); dPercentage of patients who scored the worst or best 
possible score; eSpearman’s correlation coeffi cient (Rs) for correlation of Hb level and VAS, SF-36 and 
MFI- subscales; fd= Cohen’s d. Patients with Hb level < 9.5 g/dL (e.g. median Hb level) were compared 
with patients with Hb level > 9.5 g/dL. *d<0.20 is small effect , **0.2<d<0.8 is medium effect and 
***d>0.8 is large effect.
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Correlation HRQoL and hemoglobin value
Table 2 also shows the correlation between Hb value and scores of the HRQoL ques-
tionnaires. A correlation of 0.29 (P = 0.05) was found for VAS. For SF-36, correlations 
between Hb and subscales physical functioning, role physical, vitality and physical sum 
score were statistically signifi cant. Other subscales were not signifi cantly correlated. Cor-
relation between the MFI subscales physical fatigue and reduced activity, and Hb level 
were signifi cant. Th ere was a trend towards signifi cance for mental fatigue and reduced 
motivation. Figure 1 shows the correlation between MFI subscale physical fatigue and 
Hb level. 
Th ere was a medium eff ect of the Hb level on VAS score (0.23). In particular, the Hb 
level showed medium-to-large eff ects on the physical domain of fatigue. Th is was also 
shown by the medium to large eff ects of the Hb level on the physical domain of the SF-36 
scores.
No relationship between any outcome parameters (e.g. Hb, age, HRQoL scores) was 
found with MDS subtype.
Figure 1. Correlation Hb level and physical fatigue
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Rs=-0.31 (p=0.03) 
Correlation between physical fatigue, measured with MFI, and Hb level. MFI scores range form 4 to 20 
(4=best, 20=worst). Spearman’s correlation coeffi cient is signifi cant.
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DISCUSSION
In the present study, three internationally established HRQoL measures SF-36, VAS and 
MFI, were evaluated in MDS patients. Th ese measures proved to be useful in describing 
HRQoL in MDS patients. Additionally, an association between Hb level and HRQoL was 
found.
Data collection with the three measures was feasible in this population. One patient fi lled 
in the SF-36 and VAS but not the MFI, maybe as a result of problems with turning the 
pages. Completing the questionnaires was thus not diffi  cult for these patients.
MDS patients appeared to have a consistently reduced HRQoL, measured with SF-36 and 
MFI, than persons of similar age, especially on the physical dimensions. No diff erences 
for MDS subtype were found, which may be because of the small group size. All alpha-
coeffi  cients of SF-36 and MFI were greater than 0.70, making them potentially suitable 
for group comparisons. Th ese HRQoL scores may also be infl uenced by co-morbidity 
factors, which would be expected in this elderly patient group.
Th e physical domain of HRQoL was considered the primary outcome variable in this 
study. A correlation between Hb value and the physical domain of HRQoL was found. 
Th is correlation, although signifi cant, was lower than 1. Th is suggests that the HRQoL 
is aff ected by infl uences other than Hb level, which is in agreement with the literature.19 
Th us, HRQoL can only be partly explained by the Hb level.
In daily practice, evaluation of success of red cell transfusion and the clinical decision to 
transfuse has been measured only by eff ect on Hb levels.6,20,21 Th e association between Hb 
value and HRQoL found in this study indicates the need to evaluate both the Hb value 
and HRQoL when deciding whether or not to give red cell transfusions.
Further longitudinal research is needed to assess the eff ect of red cell transfusion on 
HRQoL and to confi rm the role of HRQoL in deciding whether red cell transfusion(s) 
is necessary. Th e measures tested in this pilot study are complementary and seem to be 
useful tools in future clinical trials.
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ABSTRACT
Background: A delivery may have a major impact on the health-related quality of life 
(HRQoL) of the new mother, especially on fatigue. A common complication during 
delivery that might have a relationship with maternal morbidity is blood loss. Th e ob-
jectives were to investigate fatigue and HRQoL in women aft er vaginal delivery (VD), 
elective caesarean section (CS) and emergency CS and its relationship with postpartum 
hemoglobin (Hb) levels during the fi rst six weeks postpartum.
Study design and methods: 141 patients (71 aft er VD, 36 aft er elective CS and 34 aft er 
emergency CS) completed the HRQoL questionnaires MFI and EQ-5D between 12-24 
hours aft er VD and 24-48 hours aft er CS (T=0). One, three and six weeks postpartum 
these questionnaires were repeated, together with the SF36.
Results: Patients aft er VD had higher mean physical HRQoL scores than aft er CS. Th e 
average period to reach full physical recovery was three weeks aft er VD, six weeks aft er 
elective CS and more than six weeks aft er emergency CS. Mean mental HRQoL scores of 
the study groups were similar or even better compared to reference values. Th e signifi -
cant correlation between Hb level and mean physical HRQoL scores, found at T=0, had 
disappeared at one week postpartum.
Conclusion: Results of this study provided insights into the natural course of fatigue and 
HRQoL postpartum. Important diff erences in fatigue and HRQoL scores were observed 
between the three modes of delivery. Th ese HRQoL measures can be used in future clini-
cal trials to assess the eff ects of interventions postpartum.
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INTRODUCTION
Th e birth of a child may have a major impact on the health-related quality of life (HRQoL) 
of the new mother. Traditionally the postpartum period is considered to be six weeks, the 
period the reproductive organs need to recover.1 Longitudinal studies measuring HRQoL 
during the fi rst year postpartum are available, describing serious physical and emotional 
problems (e.g. breast discomfort, urine incontinence, back pain, fatigue, depression and 
sexual problems postpartum).2,3 Some of these symptoms are still present more than 12 
months postpartum.4 With an incidence of 60- 70% fatigue is a common symptom one year 
postpartum.2,4 Furthermore, HRQoL in patients aft er vaginal deliveries was found to be dif-
ferent compared to patients with cesarean deliveries.3 Th e fatigue is not an isolated physical 
symptom but rather involves lethargy, decreased mental alertness, physical weakness, and 
poor concentration. HRQoL is a multidimensional concept with physical, psychological 
and social domains. It can be measured in terms of ‘objective’ functioning (what the patient 
is able to do) and, complementary, in terms of the patient’s subjective evaluation thereof. To 
date, studies about fatigue and HRQoL in the immediate postpartum period are lacking.
One of the most prevalent delivery related complications that might have consequences 
on maternal HRQoL, and especially fatigue, is blood loss. Th e circulating blood volume 
increases during pregnancy to 100 mL/kg constituting to an average total blood volume 
of six-seven liters. Th e several blood components contribute diff erently to this increase: 
plasma increases with 40% whereas erythrocyte volume increases with 15-20%. Con-
sequently, hemoglobin (Hb) level decreases with a maximum of approximately 10%.5 
Th is natural process of hemodilution improves the placental circulation. In addition, the 
blood coagulation system will be activated which reduces the risk of extensive blood 
loss during parturition and thus postpartum anemia. During the fi rst three days aft er 
delivery the redistribution of extracellular fl uid induces a further decrease in Hb level. 
From the third day postpartum Hb levels start to increase and return to normal values 
six weeks postpartum. Forty percent of the patients suff er from more than 500 mL blood 
loss aft er vaginal delivery (VD).6 Blood loss of more than 1000 mL complicates 30% of 
the patients undergoing a caesarean section (CS) and 70% of the patients undergoing a 
CS in combination with a hysterectomy.6 Th e most important consequence of obstetric 
hemorrhage is anemia, with severe fatigue as a common symptom.7
Th e goals of this study were to establish the natural course of fatigue and HRQoL during 
the fi rst six weeks postpartum. Internationally established HRQoL measures were used 
to measure fatigue and generic HRQoL in patients aft er diff erent modes of delivery dur-
ing the fi rst six weeks postpartum. In addition, the relationship between Hb values and 
fatigue was assessed.
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MATERIALS AND METHODS
Th e Ethics Committees of the three participating hospitals approved the study protocol. 
Because patients were only asked to fi ll in HRQoL questionnaires, patients did not have 
to give informed consent.
Patients
In the period of June 2003 till March 2004, 71 consecutively patients aft er VD and 70 
consecutively patients aft er CS were included in two university hospitals and in one 
general hospital in the Netherlands. Th is prospective cohort study was performed in the 
three participating hospitals, coordinated by one researcher (AJGJ). Th e inclusion was 
performed consecutively: the fi rst 61 patients (31 aft er VD and 30 aft er CS) entered the 
study in the fi rst hospital, followed by 60 patients (30 aft er VD and 30 aft er CS) in the sec-
ond hospital and fi nally 20 patients (10 aft er VD and 10 aft er CS) in the third hospital. So 
we recruited for 10 months: on average three months in the fi rst hospital, three months 
in the second hospital and one month in the third hospital. Patients undergoing CS were 
grouped into those undergoing an elective CS (N= 36) and those undergoing an emer-
gency CS (N=34). Indications for elective CS were breech and transverse presentation, 
two or more previous caesarean sections, previous anorectal surgery, maternal condition 
and a previously complicated VD.
Emergency CS was defi ned as a CS performed during labor. Recruitment of the patients 
took place 12-24 hours aft er VD and 24-48 hours aft er CS (time point T=0). Th e larger 
delivery-study interval in the CS group was chosen to reduce possible short-term eff ects 
of the surgery procedure itself. All patients who underwent CS received spinal anesthesia. 
Other inclusion criteria were maternal age older than 18 years and working knowledge 
of the Dutch language.
HRQoL questionnaires
Th e HRQoL questionnaires used in the present study included both objective and subjec-
tive elements. Th e Multidimensional Fatigue Inventory (MFI) was chosen to measure 
fatigue. Th e MFI was originally developed to assess fatigue comprehensively in cancer 
patients during radiotherapy.8,9 Th e measure covers fi ve dimensions: General Fatigue, 
Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each di-
mension is addressed by fi ve items, with 4 response choices per item. Each scale has a 
score, which ranges from 4 to 20 (4=optimal).
It is common practice to combine condition-specifi c and/or domain-specifi c measures 
with generic measures, allowing for comparison of HRQoL scores across disease stages 
and diagnostic groups. Th e generic measures EuroQoL 5D (EQ-5D)10, including the 
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Visual Analogue Scale (VAS) for self-related health, and the Short-Form 36 (SF36) were 
used.11-13 Th ese measures have a high feasibility, reliability and validity and are interna-
tionally standardized and widely used.
Th e EQ-5D instrument was developed by the international EuroQoL Group as a stan-
dardized generic measure for description of health status.10 Th e descriptive part of the 
5D-version consists of fi ve items (Mobility; Self-Care; Usual Activities; Pain/Discom-
fort; Anxiety/Depression), each following the general form: 1 = no problems, 2 = some 
problems, 3 = extreme problems. Th e sixth item, the VAS, is a global evaluation of own 
health with a range from 0 (worst imaginable health state) to 100 (best imaginable health 
state).
Th e generic measure SF36, developed in the United States, was derived from the larger 
battery of health status instruments employed in the Medical Outcomes Study.11-13 It 
consists of 36 items, organized into eight scales: Mental Health, Physical Functioning, 
Role Physical, Role Emotional, Social Functioning, Bodily Pain, General Health Percep-
tions, and Vitality. Th e number of response choices per item ranges from two to six. 
Th e SF36 yields an eight-dimensional profi le, with each scale having a range from 0 to 
100 (100=optimal). Th e SF36 furthermore provides a physical sum score (PCS) (pre-
dominantly based on the scales Physical Functioning, Role Physical, Bodily Pain and 
General Health Perceptions) and a Mental sum score (MCS) (e.g. scales Mental Health, 
Role Emotional, Social Functioning, and Vitality) were computed (range 0 to 100, 100 
= optimal).13 Physical and Mental sum scores were constructed so that the general US 
population had a mean score of 50 and a standard deviation of 10. Th e Dutch version 
of the SF36 employed in the current study was developed as a part of the International 
Quality of Life Assessment (IQOLA) Project, whose objective is to translate, validate, and 
norm the SF36 in a wide range of languages and cultural settings.14
Th e fi rst set of questionnaires was completed within 12 - 24 hours aft er VD and within 
24 – 48 hours aft er CS (T=0). Simultaneously, the Hb levels were measured according to 
routine hematological examination. Th ree patients (one with VD and two with emer-
gency CS) received RBC transfusions between delivery and the moment of recruitment. 
Patients were treated postpartum, if necessary, with oral iron and folic acid therapy. One, 
three and six weeks aft er delivery (time points T=one, three and six) again the EQ-5D 
and MFI together with the SF36 questionnaires were completed at home. Th e SF36 ques-
tionnaire refers to HRQoL during the preceding week. Th erefore this questionnaire was 
not used at T=0.
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Statistics
Patients undergoing VD or CS were analyzed separately. Patients undergoing CS were 
posthoc grouped into elective CS (N=36) and emergency CS (N=34). P-values < 0.05 
were considered signifi cant.
HRQoL questionnaires
In SF36 constructed values for missing values were imputed following guidelines in the 
manual. Feasibility (completion time) and reliability (Cronbach’s alpha) were measured. 
A Cronbach’s alpha of more than 0.7 was considered reliable.15 For EQ-5D VAS, SF36 and 
MFI mean scores and standard errors were computed per scale.8,13 Diff erences between 
the three modes of delivery were analyzed using repeated measurement ANOVA, us-
ing an unstructured covariance matrix. Th e hypothesis was if the overall mean levels 
of fatigue and HRQoL were diff erent for the three study groups. It was verifi ed, using 
appropriate interaction terms, that the factor center did not aff ect the results. Scores of 
SF36 en EQ-5D VAS were compared with reference scores of the age-matched female 
Dutch population (“references”). For MFI, no reference scores are available.
The relationship between fatigue and Hb values
Th e relationship between the Hb values at time point T=0 and the scores of the diff erent 
MFI subscales at the diff erent time points was investigated using Spearman correlation 
coeffi  cients.
RESULTS
All patients met the inclusion criteria in the period of enrollment and all eligible women 
accepted to participate. Th e included patients were comparable with the total population 
of women given birth in our region. Baseline demographics of the patients aft er VD, aft er 
elective CS and aft er emergency CS are shown in Table 1. No diff erences were found for 
Hb values of the three study groups between the three hospitals (data not shown). From 
the 71 patients aft er VD, 18 patients had an instrumental VD. No baseline diff erences in 
EQ-5D including VAS, SF36 and MFI scores and recovery time were found between pa-
tients aft er spontaneous VD and instrumental delivery. Only a small diff erence between 
patients aft er spontaneous VD and instrumental VD in recovery time was measured with 
SF36 subscale SF (P=0.03) (data not shown).
Validation of HRQoL questionnaires
At six weeks postpartum 62% of the patients aft er VD, 53% of the patients aft er elective 
CS and 65% of the patients aft er emergency CS returned the HRQoL questionnaires. Th e 
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refusals did not diff er between the study groups. At the various time points, the scores 
of VAS, SF-36 and MFI spread well within ranges. Th e HRQoL questionnaires showed a 
high feasibility with a mean completion time of 10 minutes and a low amount of missing 
values: the mean amount of missing values (range) of the returned HRQoL measures for 
the time points combined was 1.8 for the MFI, 1.1 for EQ-5D classifi cation, including 
VAS, and 0.3 for SF-36. With Crohnbach’s alphas > 0.7 for all HRQoL subscales, except 
SF36 BP (> 0.5), the HRQoL measures showed a high reliability.
Fatigue scores
Scores of the MFI questionnaire are shown in Table 2. Th e maximum diff erence at the 
diff erent time points between mean MFI Physical Fatigue scores of patients with a physi-
ological VD and patients with an instrumental VD was 1.6 (P=0.25, data not shown). 
No diff erences were found between patients aft er VD with and without instrumental 
delivery for other fatigue subscales. Repeated measurements ANOVA showed that pa-
tients who underwent an elective CS had signifi cantly higher overall mean fatigue scores 
than patients aft er a VD for fatigue subscales General Fatigue (P<0.001), Physical Fatigue 
(P<0.001) and Role Physical (P = 0.026). Patients aft er emergency CS had higher overall 
fatigue scores (i.e. more fatigue) for the subscales General Fatigue (P=0.01), Physical Fa-
tigue (P<0.001), Reduced Activity (P<0.001) and Mental Fatigue (P=0.032) than patients 
aft er VD. Results of MFI subscale Physical Fatigue are shown in Figure 1. No diff erences 
were found in changes over time between the three study groups. For Mental Fatigue 
scores, no diff erences were found between the three study groups (P>0.05).
Generic HRQoL scores
Scores of SF36 using Repeated measurement ANOVA are shown in Table 3. Patients 
aft er VD had signifi cantly higher (i.e. better) mean HRQoL scores measured with the 
generic questionnaires than patients aft er elective CS. Patients aft er emergency CS had 
lower SF36 scores than patients aft er elective CS and VD. Patients aft er VD needed on 
Table 1. Patient characteristics
Vaginal Delivery
(N=71)
Elective Caesarean 
Section
(N=36)
Emergency Caesarean 
Section (N=34)
Age (Years), mean ± sd 30.5 ± 5.7 30.5 ± 5.4 32.4 ± 5.4
Gestational age at delivery 
(weeks, mean ± sd)
38.9 ± 2.6 37.3 ± 3.1 39.7 ± 1.8
Hemoglobin value (g/dL)* 11.1 (7.0 – 15.0) 10.6 (7.5 - 13.7) 10.3 (7.2 - 13.3)
Singleton 68 (96%) 35 (97%) 33 (97%)
Primiparous 23 (32%) 11 (31%) 15 (44%)
* Hemoglobin values were measured 12-24 hours after vaginal delivery or 24-48 hours after cesarean 
section. Median (minimum-maximum) is shown.
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average three weeks to reach mean normal HRQoL scores of the physical subscales 
Physical Functioning and Role Physical whereas patients aft er elective CS needed six 
weeks. Patients aft er emergency CS needed more than six weeks to reach mean scores 
of the normal population of the physical HRQoL scales Physical Functioning (P<0.001) 
and Role Physical (P<0.001). No diff erences were found in changes over time between 
the three study groups. No diff erences were found between patients with and without 
instrumental delivery.
Th e diff erences in general HRQoL scores between the three study groups may be explained 
by diff erences in physical HRQoL e.g. Role Physical (Figure 2) and Physical Functioning 
(Table 3). No signifi cant diff erences were found for mental HRQoL between the three 
study groups (P>0.05). Mean mental HRQoL scores were even slightly higher than mean 
scores of age and sex matched Dutch reference values. Results of EQ-5D and VAS are 
comparable with the results of the SF36 questionnaire and are shown in Table 4.
The relationship between fatigue and Hb values
A signifi cant, but weak, correlation between Hb values and fatigue scores at 12-24 hours 
aft er VD and 24-48 hours aft er CS (time point T=0) was found for MFI subscales General 
Fatigue (P=0.002), Physical Fatigue (P=0.001), Reduced Activity (P=0.013) and Reduced 
Figure 1. Scores of MFI subscale Physical Fatigue at four different time points in women after three 
modes of delivery.
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Motivation (P=0.047). However, Hb values at time point T=0 were not signifi cantly re-
lated to fatigue and generic HRQoL scores one, three and six weeks postpartum (except 
for MFI Reduced Activity at three weeks postpartum, P=0.02). No correlation between 
Hb values at time point t=0 and mental fatigue scores was found. Using ANOVA, taking 
into account the type of delivery groups, correlations between Hb and HRQoL outcomes 
were not signifi cant at one, three and six weeks postpartum.
DISCUSSION
Fatigue is an important symptom aft er delivery. So far, diff erent prospective health sur-
veys of pregnant women have been published, which showed decreased physical HRQoL 
scores during pregnancy with lower scores in the third trimester.16,17 In the present study, 
a set of internationally established methods for HRQoL measurement, measuring fatigue 
in all its domains, appeared to be feasible in clinical patients aft er delivery. At six weeks 
postpartum our data from the SF-36 were comparable with previously published data.18
Figure 2. Scores of SF-36 subscale Role Physical at three different time points in women after three 
modes of delivery.
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SF36 Role Physical was assessed at three different time points. The scale ranges from 0 to 100 (0 
= worst, 100 = best). Mean ± s.e.m are shown (repeated measurement ANOVA model). A signifi cant 
difference between mean scores of patients after vaginal delivery and mean scores of patients after 
emergency CS was found. No differences were found after six weeks for mean scores of patients after 
vaginal delivery and elective CS.
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One of the most interesting fi ndings was the diff erence in recovery time between the 
three study groups, which was consistently observed with all three HRQoL measures. 
Aft er VD the time to complete recovery was three weeks, whereas aft er elective CS pa-
tients needed six weeks to reach normal non-pregnant values. Patients aft er emergency 
CS were not fully recovered even aft er six weeks. Th e diff erences at six weeks between 
types of delivery are according to the literature.3 Postpartum patients had higher, but not 
signifi cant, mental HRQoL scores than the scores during pregnancy from the studies 
Table 4. EQ-5D scores (% patients who answered “no problem”) and VAS scores (mean (s.e.m.))
Vaginal Delivery Elective CS Emergency CS
Mobility
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
35.2
63.0
88.5
95.5
90.0
13.9
48.0
73.7
94.7
0
24.1
60.7
95.5
Self-care
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
63.4
85.2
96.2
97.7
97.9
22.2
80.0
94.7
100.0
8.8
72.4
89.3
100.0
Usual Activities
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
19.7
38.9
63.5
93.2
85.3
8.3
12.0
31.6
73.7
2.9
13.8
17.9
59.1
Pain/ discomfort
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
15.5
24.1
67.3
84.1
67.3
2.8
16.0
42.1
89.5
2.9
6.9
35.7
59.1
Anxiety/ depression
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
90.1
85.2
90.4
97.7
87.2
83.3
84.0
94.7
89.5
76.5
62.1
82.1
86.4
VAS
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
67.8 (2.0)
74.7 (2.0)
80.8 (1.9)
86.4 (1.6)
63.3 (2.8)
69.1 (2.9)
76.1 (2.9)
83.3 (2.4)
55.1 (2.9)
61.6 (2.8)
69.5 (2.6)
77.1 (2.2)
*Controls are female and age matched Dutch subjects.33
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previous mentioned.16,17 Th is was independently of the type of delivery. Confl icting data 
are published about these fi ndings in the literature. Th e latter fi nding corresponds to the 
general idea of the “happy young mother being on a pink cloud”. Another possibility 
might be that these questionnaires were not sensitive enough to discriminate between 
type of delivery for mental health.
VD is the most physiological route of delivery, which may well explain the diff erences in 
physical HRQoL scores between VD and CS. Patients undergoing an emergency CS ex-
perienced both labor and an operative procedure, which may explain the worse HRQoL 
scores. Patients undergoing an elective CS experienced the eff ect of an operation. Th e 
eff ects of surgery and anesthesia might be of more infl uence on the HRQoL scores than a 
VD. From an HRQoL point of view, it might be concluded that emergency CS should be 
prevented as much as possible. Patients at high risk of undergoing emergency CS should 
be closely monitored to off er timely elective CS. Early recognition of such patients might 
be achieved by using for example a recently published risk-scoring system.19 Also, greater 
support and care for women who underwent CS seems necessary.
Several variables may infl uence HRQoL of patients aft er delivery e.g. duration of gesta-
tion at delivery and condition of the child. We choose only to investigate the role of 
anemia, a common problem aft er delivery, which also may infl uence HRQoL. In this 
study a correlation between Hb levels and physical HRQoL scores was found 12-24 
hours aft er VD and 24-48 hours aft er CS. However, this correlation had disappeared one 
week postpartum. Red blood cell (RBC) transfusion is one of the principle treatments 
for postpartum anemia. Th e incidence of RBC transfusion aft er primary postpartum 
hemorrhage varies between <1% and 4% for VD (20-26), and between 1% and 7% for 
CS.20-30 Th e attitude of physicians toward RBC transfusion in patients undergoing CS 
has lately been evaluated.31 Th is study showed large diff erences in criteria for postpar-
tum transfusion between physicians and consequently recommended unifi cation of the 
protocols. In general, the indication for a RBC transfusion is based on Hb thresholds.32 
Th e aim however, of RBC transfusions postpartum is not to increase Hb values, but to 
treat severe fatigue and to prevent the consequences of hypoxia, severe hypovolemia and 
shock. Th e results of this study may indicate a short-term eff ect of postpartum Hb levels 
on fatigue and HRQoL scores. Although RBC transfusions should be aimed at improv-
ing fatigue and HRQoL, HRQoL questionnaires are not applied in the clinical decision 
involving blood transfusions yet. Currently, a multicenter trial, the WOMB study (Well 
being of Obstetric Patients on Minimal Blood transfusions) (ClinicalTrials.gov identifi er: 
NCT00335023) is ongoing. Th e questionnaires used in the WOMB study were validated 
in the present study.
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Th e limitations of this study include the small sample size, the low response rate and 
the lack of information about the HRQoL of the patients before delivery. Th e sample 
size of 141 patients is large enough to obtain reference values for fatigue and health re-
lated quality of life postpartum. Although there is lack of information about the HRQoL 
scores of patients before delivery, the patients of our study might be comparable with 
the general population who give birth in our region. Th is is because half of the patients 
were included in university hospitals and the other half in a general hospital; the patients 
were included consecutively and no diff erences were found in patient characteristics. 
However, this sample size is too small to measure the infl uence of possible confound-
ers on fatigue and health related quality of life e.g. age, nulli,/multipara, comorbidity, 
socioeconomic status and previous complications. Th ere was a low response rate of the 
questionnaires of 53-65% at T = six weeks, despite the recall by telephone. However, 
because no diff erences were found between the mode of delivery and all three measures 
showed a low percentage of missing values and completing the questionnaires was not 
diffi  cult for these patients, these questionnaires were considered reliable.
In conclusion, the data from this study provide detailed insights in the natural course 
of fatigue and HRQoL aft er VD and aft er CS. Th ey can be used as reference in clinical 
trials to assess the eff ects of obstetrical interventions, such as blood transfusion aft er 
obstetric hemorrhage, on postpartum HRQoL. Th e ultimate goal would be to develop an 
alternative transfusion policy, not solely based on Hb levels but in which HRQoL values 
are also taken in to account.
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ABSTRACT
Background: We examined the psychometric properties of three internationally estab-
lished measures for Health Related Quality of Life (HRQoL) in women aft er vaginal 
delivery (VD), elective caesarean section (CS) and emergency CS.
Study design and methods: Prospective longitudinal study. 141 consecutive patients (71 
aft er VD, 36 aft er elective CS and 34 aft er emergency CS) were enrolled in 2 university 
hospitals and 1 general hospital in the period June 2003 till March 2004. Women com-
pleted the Multi-dimensional Fatigue Inventory (MFI) and the EQ-5D classifi cation of 
own health between 12-24 hours aft er VD or 24-48 hours aft er CS (t=0). Subsequent 
assessments, additionally including the Short Form 36 (SF-36), were made at 1, 3 and 
6 weeks aft er delivery. We analyzed feasibility (response, completion time, reported 
diffi  culties, item non response), reliability (Cronbach’s alpha), discriminative validity 
between groups by type of delivery, and responsiveness over time. (Wilcoxon’s signed 
rank tests and eff ect sizes).
Results: Th e MFI, SF-36 and EQ-5D proved to be highly feasible and reliable (alpha >0.7 
for all scales of MFI and SF-36) in this group of respondents. Th e measures were able to 
discriminate between groups by mode of delivery, and to detect moderate recovery in 
physical and small recovery in mental status over time in the fi rst 6 weeks aft er delivery. 
Th e suboptimal total questionnaire response of 60% aft er 6 weeks was attributable to low 
response among women of non-Dutch ethnic origin.
Conclusion: Th e combination of MFI, SF-36 and EQ-5D showed good psychometric 
performance and is a good choice to measure HRQoL aft er delivery. Additional eff orts 
need to be made to increase response rates among immigrants.
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INTRODUCTION
Patient-reported outcomes, including health-related quality of life (HRQoL), have in-
creasingly been incorporated in the evaluation of medical interventions. HRQoL is oft en 
defi ned as patient-reported functioning and well being in the physical, psychological and 
social domains. Generally, there are three types of HRQoL measures:
1) generic measures, intended for use both in general population surveys and in studies 
of patients with diverse health conditions, allowing for comparison of HRQoL scores 
across disease stages and diagnostic groups
2) condition-specifi c measures, developed for use among specifi c patient population 
(e.g. cancer, diabetes)
3) domain-specifi c measures, for measurement of specifi c symptoms (e.g. fatigue, pain)
It is common practice to combine condition-specifi c and/or domain-specifi c measures 
with generic measures. Th e feasibility and other psychometric properties of HRQoL 
measures, however, may diff er between populations.
Blood loss during delivery is one of the most frequently occurring delivery related com-
plications that may have consequences for maternal HRQoL, e.g. because of excessive 
fatigue. Red blood cell (RBC) transfusion is one of the primary treatments for the result-
ing postpartum anemia. In general, the medical indication to give a RBC transfusion 
postpartum is based on Hb thresholds.1 Th e main purpose however, of RBC transfusions 
postpartum is not to increase Hb values, but to improve HRQoL. HRQoL data are not 
applied in clinical decision-making process regarding blood transfusions yet. When 
planning a study on the HRQoL eff ects of a novel RBC transfusion policy aft er deliv-
ery, we tested the appropriateness of HRQoL measures including the domain-specifi c 
Multidimensional Fatigue Inventory (MFI) for fatigue and two generic measures (Short 
Form 36 (SF-36) and the EQ-5D classifi cation of own health) among women aft er vaginal 
delivery (VD), elective caesarean section (CS) and emergency CS. Th e objectives of this 
study were to assess, in a clinical obstetrical setting:
1. the feasibility of the MFI, SF-36 and EQ-5D (indicators: response rate, missing/non-
unique answers, reported diffi  culties, and completion time)
2. the score distribution of the MFI, SF-36 and EQ-5D (mean scores, standard devia-
tions, presence of fl oor and ceiling eff ects)
3. the reliability of the scales of MFI and SF-36 (internal consistency)
4. the discriminative ability of the MFI, SF-36 and EQ-5D rating of own health between 
groups of women by type of delivery 1 week aft er delivery
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5. the responsiveness over time of the MFI, SF-36 and EQ-5D rating of own health (dif-
ferences between mean scores at T=0 and T=6 weeks, and eff ect sizes)
MATERIAL AND METHODS
Patients
In the period June 2003 till March 2004, 71 consecutive patients aft er VD and 70 patients 
aft er CS were included in two university hospitals and in one general hospital in the 
Netherlands. Patients undergoing CS were posthoc divided into those undergoing an 
elective CS (N= 36) and those undergoing an emergency CS (N=34). Inclusion criteria 
were: maternal age older than 18 years and proper knowledge of the Dutch language. 
Details of the study have been published previously.2 Ethnic origin was defi ned according 
to the criteria of Statistics Netherlands.3 If a woman herself and at least one of her parents 
were born abroad, or if a woman was born in the Netherlands but at least one of the 
parents were born abroad, she was classifi ed as being of non-Dutch ethnic origin.
HRQoL measures
MFI
Th e originally Dutch Multidimensional Fatigue Inventory (MFI) was developed as a tool 
to comprehensively assess fatigue in cancer patients.4,5 Nowadays the English translation 
is available. Th e questionnaire covers fi ve dimensions: General Fatigue (GF), Physical Fa-
tigue (PF), Mental Fatigue (MF), Reduced Motivation (RM) and Reduced Activity (RA). 
Each dimension is covered by a fi ve-item scale. Th e number of response choices per item 
is four. Each scale has ranges from 4 to 20 (4=optimal). Reference scores are available for 
MFI, but not by age and sex, so that we could not use these.6
SF-36
Th e generic SF-36 version 1 was developed in the United States from the larger battery of 
health status instruments employed in the Medical Outcomes Study.7-10 It consists of 36 
items, organized into eight scales: Physical Functioning (PF), Role-Physical (RP), Bodily 
Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional 
(RE) and Mental Health (MH). Th e number of response choices per item ranges from 
two to six. Th e SF-36 yields an eight-dimensional profi le, with each scale having a range 
from 0 to 100 (100=optimal). Th e SF-36 furthermore provides a physical summary score 
(PCS; predominantly based on the scales PF, RP, BP and GH) and a mental summary 
score (MCS relating to VT, SF, RE and MH).11 PCS and MCS were constructed so that 
the general US population had a mean score of 50 and a standard deviation of 10. Th e 
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Dutch version of the SF-36 employed in the current study was developed as a part of the 
International Quality of Life Assessment (IQOLA) Project, whose objective is to trans-
late, validate, and norm the SF-36 in a wide range of languages and cultural settings.12,13 
Reference scores by age and sex were available from Aaronson et al.12
EQ-5D
Th e EQ-5D classifi cation of own health was developed by the international EuroQoL 
Group.14 It consists of fi ve items (Mobility; Self-Care; Usual Activities; Pain/Discomfort; 
Anxiety/Depression), each following the general form: 1 = no problems, 2 = some prob-
lems, 3 = extreme problems. Th e sixth item is a global evaluation of own health on a 
visual analogue scale (EQ-VAS) with a range from 0 (worst imaginable health state) to 
100 (best imaginable health state). Reference scores by age and sex were available from 
Hoeymans et al.15
Timing of assessments
Women completed the MFI and EQ-5D 12-24 hours aft er vaginal delivery (VD) and 
24-48 aft er caesarean section (CS), respectively (T = 0). One, three and six weeks aft er 
delivery (time points T = 1, 3 and 6 weeks) the EQ-5D and MFI were fi lled in at home. 
Th e SF-36 was added to the latter three questionnaires. Th e questionnaires were returned 
by mail to the investigators and patients were reminded by telephone in order to increase 
the response.
Statistics
Patients
Frequencies were described as number, mean, and SDs. Diff erences in type of delivery 
were analyzed using the χ2 test.
Feasibility
Total questionnaire response, missing/non-unique answers, and the completion time were 
used as feasibility indicators. At the end of the questionnaires women could report their 
experienced diffi  culties while fi lling in the questionnaires. Missing values were defi ned 
as those cases, where no answer was given, and those where more than one response was 
given when only one was required. Completion time was defi ned as the time as reported 
by the patient required to complete the questionnaire. In addition the number of patients 
who needed help fi lling in the HRQoL questionnaire was recorded.
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Score distribution
For EQ-VAS and MFI, no constructed values for missing values were imputed. For 
SF-36, constructed values for missing values were imputed following guidelines in the 
manual aft er the item non-response analysis.16 Mean scores, standard deviations, and the 
percentages of respondents with the maximum possible score and the minimum pos-
sible score were calculated per scale. For SF-36, mental and physical summary scores 
were calculated.11 For the EQ-5D classifi cation we computed the percentages of subjects 
reporting ‘no problems’.
Reliability
Th e internal consistency of the SF-36 subscales and the MFI subscales was determined 
with Cronbach’s alpha coeffi  cient. An alpha-coeffi  cient of 0.70 or higher was considered 
as suffi  cient for the purpose of group comparisons.17 Internal consistency could not be 
measured for EQ-5D classifi cation, as it consists of one item with ordered response op-
tions per scale.
Discriminative validity
Discriminative validity was defi ned as the ability of the MFI, SF-36 and EQ-VAS to 
discriminate between groups of women by type of delivery at T=1 week. Discriminative 
validity was measured with eff ect sizes defi ned as d= [(Mean(a) – Mean(b)]/SD(pooled). 
a= scores of patients aft er VD, b= scores of patients aft er elective CS or emergency CS 
and SD(pooled)= √[(SD(a)2 + SD(b)2)/2]. Th e eff ect size (d) gives an indication of the 
clinical relevance of the statistically signifi cant diff erences. 0.20 ≤ d < 0.50 indicates a 
small eff ect, 0.50 ≤ d < 0.80 a moderate eff ect, and d ≥ 0.80 a large eff ect.17 Scores of MFI, 
SF-36 and EQ-5D classifi cation, including VAS, were compared with reference scores of 
the age-matched female Dutch population (“references”).
Responsiveness over time
Diff erences between mean scores of MFI, SF-36, and EQ-VAS at T = 0 and T = 6 weeks 
were analyzed using two-sided Wilcoxon’s signed rank tests. When scores diff ered with 
p-values < 0.05 in the expected direction (e.g. improvement) this was viewed as a sign of 
sensitivity to change of the studied measures. Moreover, an eff ect size estimation (d) was 
calculated which related the diff erence in mean scores to the dispersion in scores. Th e d 
was defi ned as = [(Mean score (a) – Mean (b)]/SD (pooled). a= scores at T=0, b= scores 
of patients at T=6 weeks and SD(pooled)= √[(SD(a)2 + SD(b)2)/2], with interpretation 
as above.
83
Psychometric evaluation of health related quality of life measures after different types of delivery
P-values <0.05 were considered signifi cant. All statistical analyses were performed using 
the SPSS package, version 11.5, for WINDOWS. Th e medical ethical review board of 
Erasmus MC, University Medical Center Rotterdam, approved this study.
RESULTS
Patient characteristics
Th e characteristics of the patients are shown in table 1. Mean age was 30.5-32.4 years for 
the three study groups, with a gestational age at delivery of 37.3-39.7 weeks. Almost all 
women had singleton births and approximately one third were primiparous. Th irty-four 
percent of the patients in the study group were of non-Dutch ethnic origin. Of the patients 
from Dutch ethnic origin, 46% had a VD, 28% an elective CS and 26% an emergency CS, 
where the percentages of patients from non-Dutch ethnic origin were 60%, 19% and 21% 
respectively (p>0.05).
Feasibility
A total of 55% of the patients returned all HRQoL measures, 16% returned three ques-
tionnaires, 9% returned two questionnaires and 20% returned only the fi rst question-
naire. Of the ethnic Dutch patients 70% returned all questionnaires, whereas only 44% of 
the ethnic non-Dutch patients returned all questionnaires. For all diff erent time points 
combined, the mean amount of missing values (range) of the returned HRQoL measures 
was 1.8 (0-4) for the MFI, 1.1 (0-3) for EQ-5D classifi cation, including VAS, and 0.3 (0-1) 
for SF-36.
Table 1. Patient characteristics
Vaginal Delivery
(N=71)
Elective Caesarean 
Section
(N=36)
Emergency 
Caesarean Section 
(N=34)
Age (Years), mean ± sd 30.5 ± 5.7 30.5 ± 5.4 32.4 ± 5.4
Gestational age at delivery 
(weeks, mean ± sd)
38.9 ± 2.6 37.3 ± 3.1 39.7 ± 1.8
Singleton 68 (96%) 35 (97%) 33 (97%)
Primiparous 23 (32%) 11 (31%) 15 (44%)
Ethnic origin (N)*
Dutch
Non-Dutch
Unknown
42
29
26
9
1
24
10
Patient characteristics. *Ethnic origin was defi ned according to the criteria of Statistics Netherlands 
(CBS 2000). If a woman herself and one of her parents were born abroad, or if a woman was born in the 
Netherlands but one of the parents was born abroad, she was classifi ed as non-Dutch ethnic origin.
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Mean reported completion time of the set of HRQoL measures at T=0 was 8.5 minutes, 
at T=1 week 11.9 minutes, at T=3 weeks 10.7 minutes, and at T=6 weeks 9.2 minutes 
(ranges 2-30 minutes). Seventeen out of the 141 patients at T=0 needed help fi lling in the 
questionnaires, 11 patients out of 141 at T=1 week, 5 patients out of 141 at T=3 weeks and 
5 patients out of 141 at T=6 weeks.
Score distribution
Mean scores, standard deviations, and the percentage of respondents showing the 
maximum and the minimum possible scores of the MFI, EQ-VAS at T=0 and T=6 weeks, 
and of SF-36 at T=1 week and T=6 weeks, are shown in table 2. At T=1 week the SF-36 
subscale RP showed a fl oor eff ect (>25% of the respondents having the lowest possible 
score), and the SF-36 scale RE showed a ceiling eff ect (>25% of the respondents having 
the highest possible score). At T=6 weeks no fl oor eff ects were seen, but the SF-36 scales 
PF, RP, BP, SF, RE, and the MFI scales RM and MF showed a ceiling eff ect. Th e distribu-
tions of most MFI scales were skewed towards the worst possible score range at T=0. Th is 
was also evidenced by the substantial percentage of respondents scoring at the lowest 
possible scale level, particularly for the functional limitations scales. At T=6 weeks the 
distributions were skewed toward the best possible score range. Figure 1 shows the MFI 
scores over time for the three study groups. In all three study-samples a wide range of 
scores was observed for all scales of SF-36 subscales. Th e results of the EQ-5D at the 
diff erent time points, e.g. the percentage of patients aft er VD, elective CS, and emergency 
CS who scored “no problem”, are shown in table 3.
Figure 1A. MFI subscale General Fatigue (mean and se)
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Emergency cesarean section
MFI subscales range from 4 to 20 (4 = best, 20 = worst). Mean ± s.e.m. are shown.
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Reliability
Cronbach’s alphas of SF-36 scales at T = 1 week and T = 6 weeks, and MFI scales at T = 0 
and T= 6 weeks are shown in table 2. All alphas were higher than 0.70, except SF-36 scale 
BP at T = 1 week (0.48) and at T = 6 weeks (0.66).
Figure 1B. MFI subscale Physical Fatigue (mean and se)
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Figure 1C. MFI subscale Reduced Activity (mean and se)
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MFI subscales range from 4 to 20 (4 = best, 20 = worst). Mean ± s.e.m. are shown.
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Discriminative validity
Mean scores and standard deviations of MFI, EQ-VAS, and SF-36 at T = 1 week are 
shown in table 4. All mean scores were lower aft er emergency CS. Especially the physical 
HRQoL scores were on average signifi cantly lower compared to patients aft er VD, as ex-
Figure 1D. MFI subscale Reduced Motivation (mean and se)
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Figure 1E. MFI subscale Mental Fatigue (mean and se)
4
6
8
10
12
14
16
18
20
t = 0 t = 1 wk t = 3 wk t = 6 wk
Time
M
ea
n 
sc
or
e
Vaginal delivery
Elective cesarean section
Emergency cesarean section
MFI subscales range from 4 to 20 (4 = best, 20 = worst). Mean ± s.e.m. are shown.
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pected. Th e eff ect sizes for the diff erences in physical scale scores were moderate between 
patients aft er elective CS and patients aft er VD. Th ey were (very) small for the mental 
subscales. Between patients aft er emergency CS and patients aft er VD, eff ect sizes for the 
diff erences between physical scale scores were moderate to large whereas the eff ect sizes 
indicated small diff erences for the mental scores.
Responsiveness over time
Th e ability of the three measures to discriminate between T = 0 (MFI, EQ-VAS)/T = 1 
week (SF-36) and T = 6 weeks within a group is shown in table 2. Th e MFI, SF-36 and 
EQ-VAS scores showed highly signifi cantly improvements in physical functioning be-
tween T=0 and T=6 weeks. Th e eff ect sizes were large with ranges between 0.91-1.68. Th e 
instruments showed smaller eff ects for improvement for mental functioning between 
T=0 and T=6 weeks, with eff ect sizes ranging from 0.42-1.29. SF-36 GH did not detect 
any changes between T=0 and T=6 weeks.
Table 3. Scores of EQ-VAS, MFI, SF-36 (mean ± SD) and effect sizes at T=1 week compared to patients 
after VD
Vaginal 
Delivery 
(N=71)
Elective 
Caesarean 
Section 
(N=36)
Effect size 
(Cohen’s d)
Emergency 
Caesarean 
Section
(N=34)
Effect size 
(Cohen’s d)
Controls*
EQ-VAS 75.0 ± 14.5 69.3 ± 15.1 0.39 61.0 ± 15.3* 0.94
MFI GF 13.1 ± 4.3 13.5 ± 4.0 0.10 16.5 ± 4.5* 0.77
MFI PF 11.4 ± 4.5 14.4 ± 4.8* 0.64 15.7 ± 5.1* 0.89
MFI RA 12.0 ± 3.8 15.0 ± 4.2* 0.75 15.0 ± 4.5* 0.72
MFI RM 8.7 ± 3.4 8.4 ± 3.7 0.08 10.1 ± 4.8 0.34
MFI MF 9.5 ± 4.7 9.5 ± 4.3 0.00 11.4 ± 5.7 0.36
SF-36 PF 59.4 ± 20.7 45.0 ± 20.8* 0.69 32.8 ± 23.1* 1.21 91.9
SF-36 RP 26.9 ± 35.0 18.0 ± 18.4 0.32 16.4 ± 28.6 0.33 83.1
SF-36 BP 44.7 ± 16.1 38.8 ± 18.4 0.34 35.6 ± 19.5* 0.51 78.9
SF-36 GH 76.5 ± 17.1 75.9 ± 19.4 0.03 72.2 ± 19.7 0.23 78.3
SF-36 VI 55.8 ± 16.7 53.8 ± 15.3 0.12 42.4 ± 19.0* 0.75 67.4
SF-36 SF 64.6 ± 24.4 53.0 ± 26.8 0.45 47.0 ± 24.2* 0.72 85.9
SF-36 RE 70.4 ± 36.4 74.7 ± 36.4 0.12 54.0 ± 46.6 0.39 81.1
SF-36 MH 81.9 ± 15.4 78.7 ± 16.2 0.20 73.8 ± 16.9* 0.50 76.4
SF-36 PSC 35.6 ± 7.7 31.5 ± 7.4 0.54 29.9 ± 7.5* 0.75 53.8
SF-36 MSC 53.6 ± 9.9 53.4 ± 9.0 0.02 48.8 ± 11.2 0.45 48.2
Means scores (SD) of EQ-5D-VAS, MFI, and SF-36, and effect sizes at T= 1 week for the different type of 
delivery. 0.20 ≤ d < 0.50 indicates a small effect, 0.50 ≤ d < 0.80 a moderate effect, and d ≥ 0.80 a 
large effect. *p ≤ 0.05, with two tailed Mann Whitney U test.
Control scores are available from Hoeymans et al, and Aaronson et al. No reference scores were 
available for MFI and EQ-VAS.12,15
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DISCUSSION
Th is evaluation of the international standard HRQoL measures MFI, EQ-5D and SF-36 
established the feasibility, reliability and validity of these measures in a clinical obstetric 
setting. Th is study supports the discriminative ability of these measures by type of deliv-
ery and provides reference (norm) scores for patients aft er delivery.
Diff erent HRQoL measures are used in studies with patients aft er delivery.18-22 However, 
to our knowledge, no psychometric evaluation of HRQoL measures has been done in 
the postpartum period. MFI has already been used to measure fatigue in patients with 
Table 4. EQ-5D scores (% patients who answered “no problem”)
Vaginal Delivery Elective CS Emergency CS
Mobility
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
35.2
63.0
88.5
95.5
90.0
13.9
48.0
73.7
94.7
0.0
24.1
60.7
95.5
Self-care
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
63.4
85.2
96.2
97.7
97.9
22.2
80.0
94.7
100.0
8.8
72.4
89.3
100.0
Usual Activities
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
19.7
38.9
63.5
93.2
85.3
8.3
12.0
31.6
73.7
2.9
13.8
17.9
59.1
Pain/ discomfort
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
15.5
24.1
67.3
84.1
67.3
2.8
16.0
42.1
89.5
2.9
6.9
35.7
59.1
Anxiety/ depression
T = 0
T = 1 week
T = 3 weeks
T = 6 weeks
Controls*
90.1
85.2
90.4
97.7
87.2
83.3
84.0
94.7
89.5
76.5
62.1
82.1
86.4
*Controls are female and age matched Dutch subjects.15
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several diseases23-26 and showed to be a useful tool to measure fatigue. On the basis of 
results of a psychometric analysis of 4 generic health measures in migraine patients, the 
SF-36 appeared to be the most suitable generic measure for describing HRQoL in that 
group of patients.27 Th e SF-36 was already validated during pregnancy, but not in the 
postpartum period.19 Th e EQ-5D appeared less sensitive probably due to the fewer items 
of this measure.14 From the literature it is known that the EQ-5D has large ceiling eff ects 
(with over 95% at the ceiling for the functional dimensions) compared to the SF-36 (37-
72%).11,14
Jomeen et al showed the SF-36 to be a potentially valuable measure in screening for the 
occurrence of HRQoL defi cits during pregnancy, especially because of the correlations 
of the SF-36 mental subscales to mood measures.19 However, the results of our study did 
not show diff erences of the SF-36 mental subscales in the fi rst six weeks postpartum. Our 
scores concerning the physical HRQoL were as expected from clinical experience. At T 
= 6 weeks most SF-36- and MFI subscales showed percentages of respondents higher 
than 25% with the best possible scale score (the ceiling eff ect). Th is limits the use of these 
measures to detect changes aft er the fi rst six weeks postpartum. Th e MFI scales showed 
Cronbach’s alphas at T = 0 and T = 6 weeks that were adequate for comparisons of scores 
at group level. Th e SF-36 scales showed adequate Cronbach’s alphas at T = 1 week and T = 
6 weeks, except for SF-36 BP, which may be due to the fact that this is a 2-item scale.9
Th is study showed the ability of the SF-36 and MFI to discriminate between groups by 
type of delivery. HRQoL postpartum may also be infl uenced by other factors than type of 
delivery, such as mother-related factors (e.g. amount of blood loss, duration of gestation, 
fi rst delivery or not, presence of co-morbid conditions) and child-related factors (e.g. the 
condition of the baby). We recommend further assessment of the validity of the MFI and 
SF-36 by comparing score patterns with clinical parameters of the patients.
Limitations of our study include the low total questionnaire response at T = 6 weeks, 
despite the recall by telephone. Subgroup analysis showed 70% of ethnic Dutch women 
returned the questionnaires, but only 44% of the patients from non-Dutch ethnic origin. 
Th is phenomenon is well known from other studies.28 Of the patients who returned the 
questionnaires, many patients completed either all questionnaires (55%) or only the one 
at T = 0 (20%). All three measures showed a low percentage of missing values. Completing 
the questionnaires was thus not diffi  cult for these patients. In the Rotterdam region, the 
proportion of pregnant women of non-Dutch ethnic origin approaches 75%. Th erefore, 
further eff orts need to be made to increase response rates among immigrants.
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Given the prevalence and, sometimes, serious consequences of fatigue aft er delivery, 
research eff orts aimed improving HRQoL postpartum. To achieve this goal the devel-
opment of a reliable and valid instrument for assessment is essential. It is anticipated 
that this line of research will contribute to a better understanding of impaired HRQoL 
postpartum, its prevalence, characteristics, course and correlates. An understanding of 
the likelihood of HRQoL impairments postpartum can enhance the health professional’s 
ability to evaluate individual cases, inform patients, and plan and evaluate therapy. Th e 
combination of MFI, SF-36 and EQ-5D showed good psychometric performance and is a 
good choice to measure HRQoL aft er delivery. Further research is needed to investigate 
the role of clinical variables of the delivery on the HRQoL of the mother and to increase 
the response rates among immigrants.
Chapter 6
92
REFERENCES
 1. Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood cell 
transfusions. Arch Pathol Lab Med 1998;122:130-8
 2. Jansen AJG, Duvekot JJ, Essink-Bot ML, et al. New insights into fatigue and health-related 
quality of life aft er delivery. Submitted
 3. CBS Index 2000;10:24-5
 4. Smets EMA, Garssen B, Bonke B, de Haes JCJM. Th e Multidimensional Fatigue Inventory 
(MFI); psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39: 
315-25
 5. Smets EMA, Garssen B, Cull A, de Haes JCJM. Application of the Multidimensional Fatigue 
Inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer 1996;73:241-5
 6. Smets EMA, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes 
JC. Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J 
Cancer 1998;78:907-12
 7. Ware JE, Sherboune CD. Th e MOS 36 item Short-Form Health Survey (SF36) I. Conceptual 
framework and item selection. Med Care 1992:30;473-83
 8. McHorney CA, Ware JE Jr, Raczek AE. Th e MOS 36-item Short-Form Health Survey (SF-
36): II Psychometric and clinical tests of validity in measuring physical and mental health 
constructs. Med Care 1993;31:247-63
 9. McHorney CA, Ware JE Jr, Lu JFR, Sherboune CD. Th e MOS 36-item Short-Form Health 
Survey (SF-36): III Tests of data quality, scaling assumptions, and reliability across diverse 
patient groups. Med Care 1994;32:40-66
 10. Stewart AL, Ware JE. Measuring functioning and well-being: Th e medical outcomes study 
approach. Durham/London: Duke University Press, 1992.
 11. Ware JE Jr. SF-36 health survey update. Spine 2000;25:3130-9
 12. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the 
Dutch Language version of the SF-36 Health Survey in community and chronic disease 
populations. J Clin Epidemiol 1998;51:1055-68
 13. Ware JE, Gandek BL, Keller SD and the IQOLA Project Group. Evaluating instruments 
used crossnationally: Methods form the IQOLA Project In: Spiker B, ed. Quality of life 
and pharmacoeconomics in clinical trials. 2nd edition. Philadelphia, PA: Lippincott-Raven 
Publishers, 1996
 14. Brooks R. EuroQoL: the current state of play. Health Policy 1996;37:53-72
 15. Hoeymans N, van Lindert H, Westert GP. Th e health status of the Dutch population as 
assessed by the EQ-6D. Qual Life Res 2005;14:655-63
 16. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation 
Guide. Boston, MA: New England Medical Centre, Th e Health Institute, 1993
 17. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic 
Press;1977.
93
Psychometric evaluation of health related quality of life measures after different types of delivery
 18. Förger F, Ostensen M, Schumacher A, Villiger PM. Impact of pregnancy on health related 
quality of life evaluated prospectively in pregnant women with rheumatic diseases by the 
SF-36 health survey. Ann Rheum Dis 2005;64:1494-9
 19. Jomeen J, Martin CR. Th e factor structure of the SF-36 in early pregnancy. J Psychosom Res 
2005;59:131-8
 20. Meyer JW, Eichhorn KH, Vetter K, et al. Does recombinant human erythropoietin not only 
treat anemia but reduce postpartum (emotional) distress as well? J Perinat Med 1995;23: 
99-109
 21. Olsson C, Nilsson-Wikmar L. Health-related quality of life and physical ability among 
pregnant women with and without back pain in late pregnancy. Acta Obstet Gynecol Scand 
2004;83:351-7
 22. Symon A, McGreavey J, Picken C. Postnatal quality of life assessment: validation of the 
Mother-Generated Index. BJOG 2003;110:865-8
 23. Martinez-Martin P, Catalan MJ, Benito-Leon J, et al. Impact of Fatigue in Parkinson’s Dis-
ease: Th e Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res 2006;15:597-606
 24. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported qual-
ity of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP 
chemotherapy. Eur J Haematol 2005;75:116-23
 25. Pijls-Johannesma MC, Pijpe A, Kempen GI, Lambin P, Dagnelie PC. Health related quality 
of life assessment instruments: a prospective study on preference and acceptability among 
cancer patients referred for radiotherapy. Eur J Cancer 2005;41:2250-6
 26. van der Plas SM, Hansen BE, de Boer JB, et al. Th e Liver Disease Symptom Index 2.0; valida-
tion of a disease-specifi c questionnaire. Qual Life Res 2004;13:1469-81
 27. Essink-Bot ML, Krabbe PFM, Bonsel GJ, Aaronson NK. An empirical comparison of four 
generic health status measures. Th e Nottingham Health Profi le, the Medical Outcomes 
Study 36-item, Short-Form Health Survey, the COOP/WONCA Charts, and the EuroQoL 
Instrument. Med Care 1997;35:522-37
 28. Kamperman AM. Deconstructing ethnic diff erences in mental health of Surinams, Moroc-
can andTurkish migrants in the Netherlands. Th esis Vrije Universiteit Amsterdam 2005

CHAPTER 7
General discussion

97
General discussion
RISKS OF BLOOD TRANSFUSION
Th e process of clinical blood transfusion is a complex chain beginning with a compre-
hensive health screening of the blood donor and ending with the clinical eff ects of the 
transfusion in the recipient (Figure 1).
Every step in this process possesses the potential risk for complication. Fortunately, more 
stringent donor screening, the increased sensitivity of blood screening and improved 
storage conditions have contributed to a decline in the rate of transfusion complications. 
IN addition, improvement of the production process of blood components, more refi ned 
leukocyte depletion, and gamma irradiation have also decreased the complication rate 
through increased mmulogical safety.1-6 However, the limitations of the microbial safety 
techniques include:
1) Transmission is only prevented on detectable pathogens
2) Detection effi  cacy is dependent on the sensitivity of the technique
3) With all techniques, detection is delayed by the window-phase (Table 1)
4) Currently, there are no available screening tests for protozoa
5) Risks of vacterial transmission persist
Th e risk of bacterial transmission in platelets and red blood cells is approximately 1 per 
3000 units transfused.7 Buff y coat derived platelet concentrates harbor an increased risk 
as they have higher storage temperatures (20°C), are pooled from multiple donors and 
have of a Sterile Connecting Device (SCD). Th e French hemovigilance system reports in-
cidences of clinical bacterial complications of 2: 100,000 and 6 viral complications in the 
period 1996 to 1998.8 Th e Dutch hemovigilance system Transfusie Reacties In Patiënten 
(TRIP) reported in 2004 5 cases of bacterial contamination, where 1 case was proved 
Figure 1. Clinical blood transfusion chain
Donor  – Blood Bank – Transfusion laboratory – Patient ward –  Patient
Table 1. Window period infections in the US3
Window period 
(days)
Risk per unit NAT window period 
reduction (Days)
Risk with NAT 
(undiluted)
HIV 22 1 : 493,000 11 1 : 986,000
HIV plus p24 16 1 : 676,000 5 1 : 986,000
HTLV 51 1 : 641,000 NA* NA*
HCV 82 1 : 103,000 59 1 : 368,000
HBV 59 1 : 63,000 25 1 : 110,000
*Not applicable
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(contamination with Bacillus Cereus). 6 Cases of viral transmission were reported (4 
CMV transmission, 1 HCV, and 1 HBV) but none could be proved.9
Remaining immunological risks include the risks of Graft -versus-Host Disease, RBC 
alloantibody formation and the occurrence of transfusion-associated acute lung injury 
(TRALI). More specifi cally, the incidence of RBC alloantibodies formation aft er elective 
surgery is approximately 8%.10 Multitransfused patients have a risk varying from 12-22% 
to develop red blood cell alloantibodies.10-13 In 2004, nine cases of TRALI were reported 
to the Dutch hemovigilance system TRIP, of which 3 could be proven and 1 was classifi ed 
as a possible case of TRALI.9 Finally, the US Food and Drug Administration reported an 
increase in the occurrence of TRALI cases from 2001 to 2003 from 15.8% to 22.3%.14
RISK REDUCTION IN CLINICAL BLOOD TRANSFUSION
Risk reduction in clinical blood transfusion can be attained through the use of more 
patient centered HRQoL criteria. In addition, other potential areas of risk reduction 
include improvement of the identifi cation procedure, a better understanding of the func-
tion of blood cells, pathogen inactivation techniques and TRALI prevention.
Health related quality of life
Anemia is associated with increased morbidity and all-cause mortality in patients with 
chronic kidney disease and in elderly patients.15-17 Various studies have recommended a 
reconsideration of transfusion policies.18-20 Currently, transfusion triggers are focused on 
laboratory parameters of the patients, i.e. the platelet count or Hb value.21-22 Th e adop-
tion of a lower transfusion trigger is a clinical method gaining acceptance as a means of 
transfusion risk reduction. For example, the most common used RBC transfusion trigger 
in the Netherlands is the “4-5-6 rule”, based on Hb and symptoms of the patients (ap-
pendix I). However, there is a wide variance in RBC transfusion policy among hospitals 
and among physicians (appendix II).
However, blood transfusion should be given to improve the health related quality of life 
(HRQoL) of the patient instead of laboratory values of the patient. Various reports in the 
literature recommend incorporation of HRQoL measures in clinical transfusion medi-
cine.23,24 Culleton et al suggest a redefi nition of “normal” hemoglobin values in the elderly 
further clinical trials to determine whether anemia correction improves quality of life 
in this population.25 Th e relationship between HRQoL and anemia has been confi rmed 
mostly in studies using recombinant erythropoietin in oncological patients. However, the 
eff ect of a physiologic anemia on the (physical) HRQoL has not yet been investigated.
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Th is thesis suggests that the internationally validated generic HRQoL measures SF36, 
EQ-5D, and the domain specifi c MFI are suitable to measure generic HRQoL and fatigue 
in patients with acute and chronic anemia. Th e Hb values of the patients could partly 
explain the lower HRQoL scores of the anemic patients, which is comparable to other 
studies that link laboratory parameters to HRQoL scores.26 Th us, HRQoL as well as Hb 
values should be involved in a new transfusion trigger model. Oncoloy has commonly 
employed the use of HRQoL scores for therapy. For example the Visual Analogue Scale 
is used in several hospitals to measure the pain level of clinical patients. Pain medication 
doses are partly based on these scores. A similar questionnaire could be applied to the 
evaluation of the physical fatigue of the patients with acute and chronic anemia.
A clinical trial that investigates the eff ect of RBC transfusion on HRQoL is the WOMB 
study: Well-being of Obstetric patients on Minimal Blood transfusions (ClinicalTrials.
gov identifi er: NCT00335023). Th e WOMB study is implementing a multicenter ran-
domized clinical trial comparing RBC transfusion treatment versus expectative therapy 
in patients with PPH resulting in anemia. Primary outcome in this study is fatigue mea-
sured with the MFI questionnaire. Th e characteristics of the questionnaires are described 
in chapter 4 to 6. Th e inclusion criteria and study design are shown in appendix III. Th e 
participating hospitals are shown in appendix IV. Figure 2 demonstated current numbers 
of included subjects.
Figure 2. Amount of included patients since the start of the WOMB study.
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Th is study contributes to a new RBC transfusion model for patients with acute anemia 
aft er PPH. Th is patient group consists in general of healthy young women. Th is will 
decrease the external validity of the study and results of this study may be therefore only 
used in these patients. In addition, logistical reasons make it diffi  cult for the WOMB 
study to be blinded. Although there are limitations, this study describes clearly the role 
of acute anemia on HRQoL. Th e WOMB study will contribute to the discussion on the 
optimal RBC transfusion triggers based on Hb values and HRQoL scores, for patients 
with acute anemia aft er PPH.
Identifi cation procedure
Th e ‘near miss’ events and the incorrect blood components transfused (IBCT) were the 
most frequently reported events, e.g. 60% in the UK.27 Near miss events are any error 
that, if undetected, could result in the determination of a wrong blood group, or issue, 
collection or administration of an incorrect, inappropriate or unsuitable component, 
but which was recognized before transfusion took place. According to the French result 
29.7% of the IBCT was due to technical failure, 17.8% to logistic failure, 51.5% to human 
error and for 1% no explanation was found.8 More attention should be given to the reduc-
tion of these ‘near miss’ events and IBCT.
Functioning of blood cells
Despite hematologic advances, there are still gaps in ourknowledge of the functioning of 
blood cells. In particular, the specifi c role of platelets is unclear. No in vitro tests are avail-
able for measurement of platelet function in vivo. Th e introduction of a pathogen inactiva-
tion technique (discussed below) could increase the storage time of platelet concentrates. 
Th is necessitates a better understanding of platelet aging. Platelet surface glycoproteins 
might play an important role in the aging of platelets.28-30 A better understanding of the 
platelet signaling process could lead to improvement of platelet concentrates.
Pathogen inactivation
A new important technique to increase microbial safety of blood components is the intro-
duction of a pathogen inactivation technique. Th e current role of pathogen inactivation 
for plasma units, platelet concentrates and RBC concentrates will be briefl y discussed 
below.
Plasma
For plasma units two diff erent techniques are already used in routine practice: the Sol-
vent Detergent treatment (SD-FFP) and the Methylen Blue treatment.31 Concerns of the 
occurrence of unexpected venous thrombotic events aft er large-volume exposure have 
made the SD-FFP method no longer applicable in the United States. However in Europe it 
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is still used.32 Plasma treated with the psoralen compound amotosalen HCL (S59) proved 
to be non-toxic and still has acceptable functional characteristics.33 Various studies have 
demonstrated the increased clinical effi  cacy of SD-FFP method when compared with 
the FFP method in patients with acquired liver disease and in patients with thrombotic 
thrombocytopenic purpera.34-36 In addition, treatment with ribofl avin (vitamin B2) and 
UV-A or visible light have shown promise in experimental trials.37-39
Platelet concentrates
Two diff erent trials showed no diff erences between platelet concentrates treated photo-
chemical treatment using the psoralen compound amotosalen HCL (S59) and for clinical 
hemostasis, hemorrhagic adverse events, and overall adverse events. Platelet components 
prepared with PCT off er the potential to further improve the safety of platelet transfu-
sion using technology compatible with current methods to prepare buff y coat platelet 
components and can be used in routine clinical practice.40,41 Other pathogen inactivation 
techniques, e.g. treatment with Ribofl avin (Vitamin B2) and photochemical treatment 
with the 8-methoxypsoralen and the 4’ aminomethyl 4,5’,8-trimethylpsoralen are more 
experimental.42,43
RBC concentrates
For RBC concentrates two diff erent pathogen inactivation methods are currently in 
an experimental phase. Th e fi rst, inactine, inactivates diff erent viruses and bacteria in 
whole blood and RBC concentrates.44-49 Concerns have been raised about the formation 
of RBC alloantibodies using this technique.50 Th e other technique uses S-303, which is a 
compound that belongs to a class of compounds called frangible anchor-linked eff ectors 
(FRALEs). FRALEs are activated by a pH shift  when added to packed red cells suspended 
in residual plasma and a red cell additive solution at neutral pH. However, also formation 
of RBC alloantibodies against S-303-treated RBCs is described.51
TRALI prevention
TRALI is a life-threatening adverse event of blood transfusion. It is the leading cause of 
transfusion-related death in the United States (FDA) (Table 2).
Clinical criteria for the diagnosis of TRALI include the criteria of Acute Lung Injury 
(ALI):
1) insidious, acute onset of pulmonary insuffi  ciency
2) profound hypoxemia PaO2/FiO2 < 300 mm Hg
3) bilateral fl uff y infi ltrates consistent with pulmonary edema
4) pulmonary artery wedge pressure less than or equal to 18 mm Hg, with no clinical 
evidence of left  atrial hypertension52
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For TRALI other criteria are:
1) new ALI temporally related to transfusion
2) the new ALI is thought to be mechanistically related to the transfusion
3) worsening of pre-existing pulmonary insuffi  ciency temporally related to transfu-
sion53
Th us the considered inciting factors of ALI should include TRALI if a blood transfu-
sion is the inciting event. Th ere are diff erent defi nitions used for the occurring time of 
TRALI: within 6 (TRIP) or 24 (SHOT) hours aft er transfusion. Two diff erent models are 
described for the explanation of the pathology of TRALI. Th e fi rst is antibody-mediated 
event whereby transfusion of anti-HLA, class I or class II, or anti-granulocyte antibod-
ies into patients whose leucocytes express the cognate antigens. Th is antibody-antigen 
interaction causes complement-mediated pulmonary sequestration and activation of 
neutrophils resulting in TRALI.54,55 Th e second model is a two-event model: the fi rst 
event is the clinical condition of the patient resulting in pulmonary endothelial activa-
tion and neutrophil sequestration, and the second event is the transfusion of a biologic 
response modifi er (including anti-granulocyte antibodies, lipids, and CD40 ligand) that 
activates these adherent neutrophils resulting in endothelial damage, capillary leak, and 
TRALI.56-58
Although lack of scientifi c evidence, the Dutch Sanquin Blood Supply Foundation 
recommends to exclude donors, who could be immunized, e.g. female donors who 
had pregnancy and donors who received red blood cell transfusion (before 1980), from 
plasma apheresis.
Table 2. Transfusion-Related Fatalities Reported to the FDA, FY 2001 to 200314
Reported Fatalities
Categories FY 2001 (%) FY 2002 (%) FY 2003 (%)
TRALI 12 (15.8) 16 (16.8) 21 (22.3)
ABO hemolytic transfusion Rx 10 (13.2) 14 (14.7) 11 (11.7)
Bacterial contamination 8 (10.5) 17 (17.9) 11 (11.7)
Other transfusion related causes 27 (35.5) 24 (25.3) 26 (27.7)
Transfusion relation not ruled out 11 (14.5) 9 (9.5) 13 (13.8)
Not transfusion related 4 (5.3) 5 (5.3) 4 (4.3)
Donor fatalities 4 (5.3) 10 (10.5) 8 (8.5)
Total 76 95 94
Abbreviation: FY, Fiscal year
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FUTURE DEVELOPMENTS IN CLINICAL BLOOD TRANSFUSION THERAPY
Recently, two approaches have been used to produce RBCs that could be transfused, 
regardless of the ABO group of the donor and recipient, the so-called “universal donor” 
RBCs. Th e fi rst approach has involved converting group A and B RBCs to group O by 
cleaving off  the terminal immunodominant sugars.59 Th e terminal galactose of group 
B RBCs is removed with the use of a recombinant α-galactosidase. Th is procedure is 
also available for group A RBCs with a N-acetyl-galactosamine as epitope. Increased 
anti-B titers are described aft er transfusion.60 Th e second approach involves masking the 
blood group antigens with polyethylene glycol (PEG).61 Clinical trials should prove the 
eff ectiveness of these new products.
Other developments to increase blood transfusion safety are blood substitutes, e.g. he-
moglobin solutions and the use of recombinant erythropoietin. Hemoglobin solutions 
have been used with success in Jehovah’s witness patients.62,63 Th e use of recombinant 
erythropoietin is increasing to reduce the amount RBC transfusions in patients with 
disease states requiring multiple transfusion, i.e. cancer patients receiving chemotherapy, 
chronic and end stage renal failure, heart failure and critically illness.64-68 However, RBC 
transfusion remains the fi rst choice of treatment for acute anemia.
CONCLUSION
Blood components have never been safer. With the recent introduction of pathogen 
inactivation methods, the international goal of zero risk of microbial blood transfusion 
complications comes within reach. To further strengthen the chain of events of the pro-
cess of clinical transfusions, more attention should be devoted to the hospital portion of 
the chain, specifi cally a more detalied understanding of the functioning of blood cells 
and not by the safety of the blood products as such. Reduction of the human errors can 
by reached by introduction of automatic computer assisted production and teaching of 
the persons who are involved in the clinical transfusion process. Also more attention 
should be given to a better knowledge of clinical transfusion practice, which leads to a 
diminished use of blood components and thereby to fewer complications.
Chapter 7
104
REFERENCES
 1. Goes EG, Borges JC, Covas DT, et al. Quality control of blood irradiation: determination T 
cells radiosensitivity to cobalt-60 gamma rays. Transfusion 2006;46:34-40
 2. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lan-
cet 2003;361:161-9
 3. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. Th e risk of transfusion-transmitted viral 
infections. Th e Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90
 4. van der Meer PF, Pietersz RN. Gamma radiation does not aff ect 7-day storage of platelet 
concentrates. Vox Sang 2005;89:97-9
 5. van de Watering LM, Hermans J, Houbiers JG, et al. Benefi cial eff ects of leukocyte depletion 
of transfused blood on postoperative complications in patients undergoing cardiac surgery: 
a randomised clinical trial. Circulation 1998;97:562-8
 6. van Hilten JA, van de Watering LM, van Bockel JH, et al. Eff ects of transfusion with red cells 
fi ltered to remove leucocytes: randomised controlled trial in patients undergoing major 
surgery. BMJ 2004;328:1281
 7. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of 
platelets: current problems and possible resolutions. Transfus Med Rev 2005;19:259-72
 8. Debeir J, Noel L, Aullen JP, et al. Th e French haemovigilance system. Vox Sang 1999;77: 
77-81
 9. TRIP Rapport 2004. Available at: http://www.tripnet.nl/pages/nl/documents/55496-
DefTriprapport_000.pdf
 10. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-im-
munisation following transfusion. Vox Sang 1996;71:216-20
 11. Fluit CR, Kunst VA, Drenthe-Shonk AM. Incidence of red cell antibodies aft er multiple 
blood transfusions. Transfusion 1990;30:532-5
 12. Ramsey G, Cornell FW, Hahn LF, et al. Red cell antibody problems in 1000 liver transplants. 
Transfusion 1989;29:396-400
 13. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and allo-immunisation in sickle cell 
disease. Th e cooperative study of sickle cell disease. Blood 1990;76:1431-7
 14. Goldmen M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA; TRALI Con-
sensus Panel. Proceedings of a consensus conference; towards an understanding of TRALI. 
Transfus Med Rev 2005;19:2-31
 15. Go AS, Yang J, Ackerson LM, et al. Hemoglobin levels, chronic kidney disease, and the 
risks of death and hospitalization in adults with chronic heart failure: the Anemia in 
Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 
2006;113:2713-23
 16. Izaks GJ, Westendorp RGJ, Knook DL. Th e Defi nition of Anemia in Older Persons. JAMA 
1999;281:1714-7
 17. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill pa-
tients. JAMA 2002;288:1499-507
105
General discussion
 18. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomised, controlled clinical 
trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care 
Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17
 19. Nuttall GA, Santrach PJ, Oliver WC Jr, et al. A prospective randomized trial of the surgical 
blood order equation for ordering red cells for total hip arthroplasty patients. Transfusion 
1998;38:828-33
 20. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly 
patients with acute myocardial infarction. N Engl J Med 2001;345:1230-6
 21. Wandt H, Frank M, Ehninger G. Safety and cost eff ectiveness of a 10 × 109/L trigger for pro-
phylactic platelet transfusions compared with the traditional 20 × 109/L trigger: a prospec-
tive comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601-6
 22. Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood 
cell transfusions: developed by the Red Blood Cell Administration Practice Guideline 
Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 
1998;122:130-8
 23. Cheson BD, Bennet JM, Kantarjian H, et al. Report of an international working group to 
standardize response criteria for myelodysplastic syndromes. Blood 2001;96:3671-4
 24. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for 
treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colo-
ny-stimulating factor: signifi cant eff ects on quality of life. Br J Haematol 2003;120:1037-46
 25. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of 
anemia on hospitalization and mortality in older adults. Blood 2006;107:3841-6
 26. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A con-
ceptual model of patient outcomes. JAMA 1995;273:59-63
 27. SHOT Annual Report 2004. Available at: http://www.shotuk.org/SHOTREPORT2004.pdf
 28. Hoff meister KM, Felbinger TW, Falet H, et al. Th e clearance mechanism of chilled blood 
platelets. Cell 2003;112:87-97
 29. Hoff meister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled 
blood platelets. Science 2003;301:1531-4
 30. Smethurst PA, Joutsi-Korhonen L, O’Connor MN, et al. Identifi cation of th eprimary col-
lagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a 
blocking phage antibody. Blood 2004;103:903-11
 31. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inacti-
vated substitute for fresh frozen plasma. Blood 1992;79:826-31
 32. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future 
prospects. Curr Hematol Rep 2003;2:495-502
 33. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemi-
cally treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers 
anticoagulated with warfarin. Transfusion 2002;42:1302-7
 34. Lin L, Conlan MG, Tessman J, Cimino G, Porter S. Amotosalen interactions with platelet 
and plasma components: absence of neoantigen formation aft er photochemical treatment. 
Transfusion 2005;45:1610-20
Chapter 7
106
 35. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfu-
sion of patients with acquired coagulopathy of liver disease. Blood 2006;107:3753-60
 36. Mintz PD, Neff  A, MacKenzie M et al. A randomised, controlled phase III trial of thera-
peutic plasma exchange with fresh frozen plasma prepared with amotosalen and UVA light 
compared to untreated fresh frozen plasma in thrombotic thrombocytopenic purpura. 
Transfusion 2006;46:1693-704
 37. Goodrich RP. Th e use of ribofl avin for the inactivation of pathogens in blood products. Vox 
Sang 2000;78(suppl 2):211-5
 38. Schuyler R. Use of ribofl avin for photoinactivation of pathogens in blood components. 
Transfus Apher Sci 2001;25:189-90
 39. Corbin F 3rd. Pathogen inactivation of blood components: current status and introduction 
of an approach using ribofl avin as a photosensitizer. Int J Hematol 2002;76(suppl 2):253-7
 40. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buff y coat platelet 
components prepared with photochemical pathogen inactivation treatment: the euroSPRITE 
trial. Blood 2003;101:2426-33
 41. McCullough J, Vesole DH, Benjamin RJ, et al. Th erapeutic effi  cacy and safety of platelets 
treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 
2004;104:1534-41
 42. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and 
bacteria in platelet concentrates using ribofl avin and light. Transfusion 2004;44:877-85
 43. Wollowittz S, Isaacs ST, Rapoport H, Spielman HP, inventors; Cerus Corporation, assignee. 
Compounds for the photodecontamination of pathogens in blood. US patent 5.399.719. 
1995, March 21
 44. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates 
using Inactine PEN110 chemistry. Vox Sang 2002;83:313-23
 45. Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and 
susceptibility to PEN110 inactivation. Transfusion 2003;43:1029-37
 46. Ohagen A, Gibaja V, Aytay S, et al. Inactivation of HIV in blood. Transfusion 2002;42: 
1308-17
 47. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC 
concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002;42:139-45
 48. Zavizion B, Serebryanik D, Serebryanik I, et al. Prevention of Yersinia enterocolitica, Pseu-
domonas fl uorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood 
by a novel pathogen-reduction process. Transfusion 2003;43:135-42
 49. Zavizion B, Purmal A, Chapman J, et al. Inactivation of mycoplasma species in blood by 
Inactine PEN110 process. Transfusion 2004;44:286-93
 50. Boston Business Journal 2003, November 18. Vitex halts fi nal-stage test of Inactine. Avail-
able at: http://boston.bizjournals.com/boston/stories/2003/11/17/daily11.html?t=printable
 51. Benjamin RJ, McCullough J, Mintz PD. Th erapeutic effi  cacy and safety of red blood cells 
treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial 
in cardiac surgery patients. Transfusion 2005;45:1739-49
107
General discussion
 52. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European Consensus 
Conference on Acute Respiratory Distress Syndrome: Defi nitions, mechanisms, relevant 
outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9:72–81
 53. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: defi nition 
and review. Crit Care Med 2005;33:721-6
 54. Ward HN. Pulmonary infi ltrates associated with leukoagglutinin transfusion reactions. 
Ann Intern Med 1970;73:689-94
 55. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-re-
lated acute lung injury. Transfusion 1985;25:573-7
 56. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated 
pulmonary endothelial damage: requirements for adherence and chemokine release. Am J 
Physiol Cell Physiol 2002;283:C1592-603
 57. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood 
cells cause acute lung injury in an animal model. J Clin Invest 1998;101:1458-67
 58. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause 
acute lung injury in an animal model. Transfusion 2003;43:633-40
 59. Goldstein J. Preparation of transfusable red cells by enzymatic conversion. Prog Clin Biol 
Res 1984;165:139-57
 60. Kruskall MS, AuBuchon JP, Anthony KY, et al. Transfusion to blood group A and O 
patients of group RBCs that have been enzymatically converted to group O. Transfusion 
2000;40:1290-8
 61. Nacharaju P, Boctor FN, Manjula BN, Acharya SA. Surface decoration of red blood cells 
with maleimidophenyl-polyethylene glycol facilitated by thiolation with iminothiolane: an 
approach to mask A, B, and D antigens to generate universal red blood cells. Transfusion 
2005;45:374-83
 62. Cothren CC, Moore EE, Long JS, Haenel JB, Johnson JL, Ciesla DJ. Large volume polymer-
ized haemoglogin solution in a Jehovah’s Witness following abruptio placentae. Transf Med 
2004;14:241-6
 63. Agrawal YD, Freedman M, Szczepiorkowski ZM. Long-term transfusion of polymerised 
bovine hemoglobin in a Jehovah’s Witness following chemotherapy for myeloid leukaemia: 
a case report. Transfusion 2005;45:1735-8
 64. Siddiqui MA, Keating GM. Darboepoetin alfa: a review of its use in the treatment of anae-
mia in patients with cancer receiving chemotherapy. Drugs 2006;66:997-1012
 65. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic re-
nal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005 Jul 20;(3):
CD003266
 66. Collins AJ, Brenner RM, Ofman JJ. Epoetin alfa use in patients with ESRD: an analysis of 
recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-8
 67. Silverberg DS, Wexler D, Blum M, et al. Erythropoietin in heart failure. Semin Nephrol 
2005;25:397-403
 68. Stubbs JR. Alternatives to blood product transfusion in the critically ill: erythropoietin. Crit 
Care Med 2006;34(5 Suppl):S160-9

CHAPTER 8
Summary

111
Summary
Aft er the introduction of blood component therapy in the 1960s, more and more atten-
tion is given to clinical transfusion medicine. Although blood transfusion is an important 
treatment in diff erent clinical settings, there are still lack of much randomized clinical 
trials. Nowadays blood transfusion can be called a safe treatment. Th is might be due to 
an increasing awareness of the eff ects and risks of blood transfusion. In clinical transfu-
sion practice a transfusion trigger is handled for the prescription of blood transfusion. 
Th is transfusion trigger is based on hemoglobin (Hb) levels for red blood cell (RBC) 
transfusion and on platelet count for platelet transfusions. Possibilities to improve the 
safety of blood transfusion are improvement of the blood components and reduction of 
the amount of blood transfusions.
Th is thesis describes 1) an in vitro study of a new pathogen technique for platelet concen-
trates and 2) a new model for RBC transfusion therapy for acute anemia. Th is model uses 
subjective health related quality of life criteria, which are validated in this thesis.
CHAPTER 1
Chapter one provides a general introduction to the history of blood transfusion and 
component therapy. Studies about the transfusion trigger for RBC transfusion and plate-
let transfusion are reviewed. Special attention is hereby given to health related quality 
of life and the role with anemia. An overview of the literature about the risks of blood 
transfusion is presented. Th e relationship between platelet transfusion and bacterial con-
tamination is described briefl y and a new pathogen inactivation technique for platelet 
concentrates is introduced.
CHAPTER 2
In chapter two functional characteristics of platelets aft er treatment with a pathogen 
inactivation technique using the psoralen compound amotosalen HCL (S59) and long 
wavelength UVA light were measured in vitro. Platelet concentrates were treated with one 
of the two diff erent processing systems: 1) the experimental clinical processing system 
T-bag S59 reduction device (SRD) or 2) the commercially available integral processing 
system Wafer SRD. Treated platelets were compared with control platelet concentrates 
in a plasma/PAS III solution. No diff erences were found in product quality variables, in 
activation, and apoptosis variables. Platelets treated with the experimental T-bag SRD 
had a signifi cant decrease in aggregation capacity and a signifi cant increase in plasma 
LDH. Th ese tests showed no diff erences for platelets treated with the commercially 
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available Wafer SRD. Th is in vitro study showed that treatment with the experimental 
T-bag SRD led to a signifi cant decrease in platelet function. However, treatment with the 
commercially available Wafer SRD had only minor in vitro eff ects on the quality of the 
platelets.
CHAPTER 3
In a retrospective study two diff erent hemoglobin transfusion triggers were compared in 
patients with acute myeloid leukemia who were treated with combination chemotherapy: 
1) a Hb transfusion trigger ≤ 4.5-5.5 mmol/L, dependent on age and symptoms and 2) a 
more liberal therapy with a Hb transfusion trigger ≤ 6.0 mmol/L. Th e restrictive transfu-
sion policy led to a signifi cant decrease of 11% of red blood cell (RBC) transfusions. No 
signifi cant diff erences were found in the incidence of infections, number of platelet units 
transfused, bleeding complications, cardiac symptoms, or response to chemotherapy. Th e 
restrictive transfusion policy, based on age and symptoms, was feasible in this clinical set-
ting and it might be concluded that a restrictive transfusion policy is safe in supporting 
clinical patients treated with intensive chemotherapy for AML. Due to its retrospective 
nature, health related quality of life (HRQoL) of these patients could not be measured.
CHAPTER 4
Chronic anemia is a common complication of patients with Myelodysplastic Syndromes 
(MDS), with fatigue as most important symptom. Chapter four deals with fatigue and 
HRQoL of this patient group. Fift y consecutive MDS patients completed once the Short 
Form-36, the Multidimensional Fatigue Inventory and the EQ-5D Visual Analogue 
Scale. Hb level was measured during the same visit. Th e questionnaires showed a high 
feasibility, reliability and validity. Compared to the age and sex matched general popula-
tion, MDS patients had worse HRQoL scores. A positive correlation between Hb level 
and HRQoL was found. Th is study provided insights into the suitability of established 
HRQoL measures for the evaluation of interventions in MDS patients. Hb values and 
HRQoL scores were complementary variables for evaluation of the severity of chronic 
anemia in patients with MDS.
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CHAPTER 5
A common complication during delivery is blood loss. Chapter fi ve describes fatigue 
and health related quality of life (HRQoL) in women aft er vaginal delivery (VD), elective 
caesarean section (CS) and emergency CS and its relationship with postpartum Hb levels 
during the fi rst six weeks postpartum. 141 patients completed the HRQoL questionnaires 
MFI, SF36 and EQ-5D during the fi rst six weeks postpartum. Patients aft er VD had higher 
mean physical HRQoL scores than aft er CS. Patents aft er VD needed on average three 
weeks for full physical recovery, patients aft er elective CS six weeks and patients aft er 
emergency CS more than six weeks. Mean mental HRQoL scores of the study groups 
were similar or even better compared to reference values. Th e signifi cant correlation 
between Hb level and mean physical HRQoL scores found at t=0, had disappeared at one 
week postpartum. Th e HRQoL measures of this study can be used in future clinical trials 
to assess the eff ects of interventions postpartum.
CHAPTER 6
Aft er the clinical examination of the HRQoL measures in chapter fi ve, psychometric 
properties of these measures were evaluated in chapter six. Feasibility (response, comple-
tion time, reported diffi  culties, item non response), reliability (Cronbach’s alpha), dis-
criminative validity between groups by type of delivery, and responsiveness over time 
(Wilcoxon’s signed rank tests and eff ect sizes) were analyzed. Th e MFI, SF-36 and EQ-5D 
proved to be highly feasible and reliable in this group of respondents. Th e measures could 
discriminate between groups by mode of delivery, and to detect moderate recovery in 
physical and small recovery in mental status over time in the fi rst 6 weeks aft er delivery. 
Aft er six weeks postpartum only 60% of the patients returned the HRQoL measures. Th is 
suboptimal total questionnaire response was attributable to a low response among women 
of non-Dutch ethnic origin. Aft er the good clinical properties of these measure described 
in chapter fi ve, the combination of MFI, SF-36 and EQ-5D showed good psychometric 
performance. Th e measures are feasible to measure fatigue and HRQoL aft er delivery. 
Additional eff orts need to be made to increase response rates among immigrants.
CHAPTER 7
Chapter seven is the general discussion of this thesis. Th e risks of blood transfusion are 
described broadly. Diff erent techniques for risk reduction are discussed, where special 
attention is given to health related quality of life and the WOMB study, a multicenter 
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randomized clinical trial that investigates the role of RBC transfusion therapy in the 
treatment of postpartum anemia and its possible eff ects on health related quality of life. 
Th e results of the WOMB study will contribute to the discussion of the optimal RBC 
transfusion policy for patients with postpartum anemia. Besides the identifi cation proce-
dure, functioning of blood cells and pathogen inactivation techniques will be discussed. 
More briefl y the prevention of transfusion-related acute lung injury (TRALI) is presented. 
Finally, future developments in clinical blood transfusion therapy are discussed.
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Samenvatting
Na de introductie van diverse bloedcomponententherapieën in de jaren ’60 is er steeds 
meer aandacht gekomen voor klinische transfusiegeneeskunde. Ondanks dat bloed-
transfusie een belangrijke behandeling is binnen diverse specialismen zijn er nog weinig 
gerandomiseerde klinische studies. Heden ten dage kan bloedtransfusie als veilig be-
schouwd worden. Dit wordt mogelijk veroorzaakt door een toegenomen bewustwording 
van de eff ecten en risico’s van bloedtransfusie. In de klinische transfusiepraktijk wordt 
een transfusietrigger gebruikt bij het voorschrijven van een bloedtransfusie. Deze trans-
fusietrigger is gebaseerd op de hemoglobine (Hb) waarde voor erytrocytentransfusies en 
het aantal trombocyten voor trombocytentransfusies. Mogelijkheden om bloedtransfusie 
te verbeteren zijn verbetering van de bloedproducten en vermindering van het aantal 
bloedtransfusies.
Dit proefschrift  beschrijft  1) een in vitro studie naar een nieuwe pathogeen inactivatie 
techniek voor trombocyten concentraten en 2) een nieuw erytrocyten transfusiemodel 
voor patiënten met een acute anemie. Dit model gebruikt subjectieve kwaliteit van leven 
criteria welke gevalideerd zijn in dit proefschrift .
HOOFDSTUK 1
In het eerste hoofdstuk wordt een algemene introductie gegeven over de historie van 
bloedtransfusie en bloedcomponententherapie. Studies over transfusietriggers voor 
erytrocyten- en trombocytentransfusies worden beschreven. Speciale aandacht gaat 
hierbij uit naar kwaliteit van leven en anemie. Er wordt een overzicht van de literatuur 
gegeven over de risico’s van bloedtransfusie. De relatie tussen trombocytentransfusie en 
bacteriële contaminatie wordt beschreven en een nieuwe pathogeen inactivatie techniek 
voor trombocytenconcentraten wordt geïntroduceerd.
HOOFDSTUK 2
In hoofdstuk twee worden in vitro functionele karakteristieken beschreven van trombo-
cyten na behandeling met een pathogeen inactivatie techniek waarbij gebruik gemaakt 
wordt van het psoraleen product amotosalen HCL (S59) en UVA licht. Trombocytencon-
centraten werden behandeld met 1 van de 2 verschillende S59 verwijderingssystemen: 1) 
het experimentele T-bag S59 verwijderingssysteem of 2) het commercieel beschikbare 
integrale Wafer S59 verwijderingssysteem. De behandelde trombocyten werden verge-
leken met controle trombocytenconcentraten in een PAS/Plasma bewaarvloeistof. Er 
werden geen verschillen gevonden in product kwaliteitparameters, mate van activatie en 
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apoptose variabelen. Trombocyten behandeld met het T-bag S59 verwijderingssysteem 
hadden een slechtere aggregatiecapaciteit en een signifi cant verhoogde plasma LDH 
concentratie. Deze testen toonden geen verschil voor trombocyten behandeld met het 
Wafer S59 verwijderingssysteem. Deze in vitro studie toonde een signifi cante afname 
in trombocytenfunctie na behandeling met het T-bag S59 verwijderingssysteem. Echter, 
behandeling met het commercieel beschikbare Wafer S59 verwijderingssysteem had 
slechts minimale eff ecten op de kwaliteit van de trombocyten.
HOOFDSTUK 3
In een retrospectieve studie werden 2 verschillende Hb transfusietriggers met elkaar 
vergeleken bij patiënten met een acute myeloide leukemie (AML) die behandeld werden 
met een combinatie chemotherapie: 1) een Hb transfusietrigger van ≤ 4.5–5.5 mmol/L, 
gebaseerd op leeft ijd en symptomen en 2) een meer liberale transfusietrigger van ≤ 6.0 
mmol/L. De restrictieve transfusietrigger leidde tot een signifi cante reductie van 11% in 
aantal erytrocytentransfusies. Er werden geen signifi cante verschillen gevonden in aantal 
infecties, aantal trombocytentransfusies, bloedingcomplicaties, cardiale klachten en res-
pons op de chemotherapie. Het restrictieve beleid, gebaseerd op leeft ijd en symptomen, 
was geschikt in deze klinische setting en er zou geconcludeerd kunnen worden dat een 
restrictief transfusiebeleid veilig als ondersteunende behandeling gebruikt kan worden 
voor patiënten die behandeld worden met chemotherapie voor AML. Vanwege het re-
trospectieve karakter van de studie kon er geen kwaliteit van leven gemeten worden.
HOOFDSTUK 4
Chronische anemie is een vaak voorkomende complicatie bij patiënten met een Myelo-
dysplastisch Syndroom (MDS), waarvan vermoeidheid het meest belangrijke symptoom 
is. Hoofdstuk vier gaat over vermoeidheid en kwaliteit van leven (KvL) in deze patiënten-
populatie. Vijft ig opeenvolgende MDS patiënten vulden eenmalig de Short-Form 36, de 
Multidimensionele Vermoeidheids Index 20 en de EQ-5D in. Het hemoglobine gehalte 
werd gemeten tijdens hetzelfde bezoek. De vragenlijsten hadden een grote feasibility, 
reliability en validiteit. MDS patiënten hadden slechtere KvL-scores dan personen uit de 
algemene populatie, gecorrigeerd voor leeft ijd en geslacht. Deze studie toonde inzicht 
in de geschiktheid van bestaande KvL vragenlijsten voor evaluatie van interventies bij 
patiënten met een MDS. Hb-waarden en KvL-scores waren complementaire variabelen 
voor de evaluatie van de ernst van de chronische anemie in patiënten met MDS.
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HOOFDSTUK 5
Een vaak voorkomende complicatie tijdens een bevalling is bloedverlies. Hoofdstuk vijf 
beschrijft  vermoeidheid en kwaliteit van leven (KvL) van vrouwen na een vaginale partus, 
geplande keizersnede en spoed keizersnede en de relatie met de postpartum Hb-waarde 
gedurende de eerste zes weken postpartum. Door 141 patiënten werden de KvL vragen-
lijsten MVI-20, SF-36 en EQ-5D ingevuld gedurende de eerste zes weken postpartum. 
Patiënten met een vaginale partus hadden hogere gemiddelde fysieke KvL-scores dan 
patiënten met een keizersnede. Patiënten met een vaginale partus hadden gemiddeld 
drie weken nodig voor volledig herstel van de fysieke KvL, patiënten na een geplande 
keizersnede zes weken en patiënten na een spoed keizersnede meer dan zes weken. De 
gemiddelde mentale KvL scores van de studiepopulatie waren gelijk of zelfs beter dan de 
referentiescores. De signifi cante relatie tussen de Hb-waarde en de gemiddelde fysieke 
KvL-scores op t=0 waren een week postpartum verdwenen. De KvL vragenlijsten van 
deze studie kunnen gebruikt worden in toekomstige klinische onderzoeken om het eff ect 
van interventies postpartum te meten.
HOOFDSTUK 6
Na de klinische evaluatie van de KvL vragenlijsten in hoofdstuk vijf worden de psycho-
metrische eigenschappen van deze vragenlijsten getest in hoofdstuk zes. De feasibility 
(respons, invultijd, gerapporteerde moeilijkheden, item non respons), reliability (Cron-
bach’s alfa), discriminerende validiteit tussen groepen bij type bevalling, en responsiviteit 
in de tijd werden geanalyseerd. De MVI-20, SF-36 en EQ-5D hadden een grote feasibility 
en reliability in deze groep respondenten. De vragenlijsten konden onderscheid maken 
binnen de studiegroep bij type bevalling en ze konden een mild herstel in fysieke en een 
klein herstel in mentale KvL gedurende de eerste zes weken na de bevalling aantonen. Zes 
weken postpartum retourneerden slechts 60% van de patiënten de KvL vragenlijsten. Deze 
suboptimale respons werd veroorzaakt door een lage respons onder allochtone patiënten. 
Na de goede klinische eigenschappen van deze vragenlijsten gemeten in hoofdstuk vijf, 
toonde de combinatie MVI-20, SF-36 en EQ-5D goede psychometrische eigenschappen. 
De vragenlijsten zijn geschikt om vermoeidheid en KvL na een bevalling te meten. Meer 
aandacht moet besteed worden aan de lage respons onder allochtonen.
Chapter 9
120
HOOFDSTUK 7
Hoofdstuk zeven is de algemene discussie van dit proefschrift . De risico’s van bloed-
transfusie worden beschreven. Verschillende technieken voor risicoreductie worden 
bediscussieerd, waarbij speciale aandacht gegeven wordt aan kwaliteit van leven en de 
WOMB studie. Deze studie is een multicenter gerandomiseerde klinische studie welke de 
rol van erytrocytentransfusies in de behandeling van postpartum anemie onderzoekt en 
hierbij de mogelijke eff ecten op KvL. De resultaten van de WOMB studie zullen bijdra-
gen aan de discussie over het optimale erytrocytentransfusiebeleid voor patiënten met 
een acute anemie. Daarnaast worden de identifi catie procedure, het functioneren van 
bloedcellen en de pathogeen inactivatie technieken besproken. Er wordt dieper ingegaan 
op de preventie van transfusion-related acute lung injury (TRALI). Uiteindelijk worden 
toekomstontwikkelingen in de klinische bloedtransfusietherapie beschreven.
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APPENDIX
APPENDIX I
Th e “4-5-6 rule” is the recommended RBC transfusion trigger in the Netherlands for 
patients with acute or chronic anemia based on the Hb value and symptoms of patients 
(see table).
Table. “4-5-6 rule”
Consider a RBC transfusion at a Hb < 4.0 mmol/l (Hct 0.20) when:
− Acute blood loss in ASA I patients < 60 years, normovolemic blood loss from one locus
− Chronic asymptomatic anemia
Consider a RBC transfusion at a Hb < 5.0 mmol/l (Hct 0.25) when:
− Acute blood loss in ASA I patients > 60 years, and normovolemic blood loss from one locus
−  Acute blood loss in healthy patients < 60 years, normovolemic blood loss from different loci (poly trauma 
patients)
− Patients < 60 years, preoperative, with an expected blood loss of more than 500 mL
− Fever
− Postoperative phase after open-heart surgery, uncomplicated
− ASA II and ASA III patients without complications
Consider a RBC transfusion at a Hb < 6.0 mmol/l (Hct 0.30) when:
− ASA IV patients
− Patients who are not capable to increase the heart-minute-volume for the compensation of the hemodilution
− Patient with sepsis or toxic patients
− Patient with a severe lung disease
− Patients with symptomatic cerebrovascular disease
ASA-criteria
I healthy persons
II patients with mild systemic disorder, without functional symptoms
III patients with severe functional limiting systemic disorder
IV patients with systemic disorder that constantly causes life threatening
V patients who are moribund and who will, with or without surgery, die probably within 24 hours
Appendix
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APPENDIX II
Th e results of a questionnaire about red blood cell transfusion policy aft er postpartum 
hemorrhage held in 2003 in 40 teaching hospitals in Th e Netherlands.
1) The RBC transfusion trigger is based on
(N)
Hb value
1
Symptoms
2
Both
29
2) Under which Hb value do you consider to give a RBC transfusion? 
(N=32), mean ± SD (range)
5,0 ± 0,53 (4,0 – 6,0) mmol/l
3) Under which Hb value do you actually give a RBC transfusion? 
(N=32), mean ± SD (range)
4,2 ± 0,51 (3,0 – 5,5) mmol/l
4) Which symptoms are important in the decision to give a RBC 
transfuse on? (more answers possible) (N=33)
– Dyspnoea
– Syncope
– Orthostatic complaints
– Tachycardia (> 100 bpm)
– Angina Pectoris
– Transient Ischemic Attack (TIA)
YES  NO
23  10
31  2
25  8
22  11
16  17
13  20
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Appendix
APPENDIX III
Inclusion criteria, study design and statistics of the WOMB study
Inclusion criteria WOMB study are:
1) Time: 12-24 h aft er VD or CS;
2) Hb level: 3.0 ≤ Hb ≤ 4.9 mmol/l;
3) PPH: blood loss ≥ 1000mL;
4) Age: age ≥ 18 years;
5) Symptoms: no anemic symptoms.
Study design WOMB study
Appendix
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Statistics
Th e sample size is based on the investigation of the relationship between fatigue (and 
HRQoL), measured with HRQoL questionnaires, and diff erent RBC transfusion trig-
gers. Th e HRQoL questionnaires are validated in the study described in chapter 5 and 6. 
Fatigue, measured with the MFI questionnaire, is the primary outcome.
Th e sample size is 400 patients: 200 patients aft er a VD (where 100 patients receive a RBC 
transfusion and 100 patients not) and 200 patients aft er a CS (also 100 patients with and 
100 patients without a RBC transfusion). With this amount of patients, diff erences per 
type of delivery (VD and CS) for HRQoL scores are detectable (α = 0.05, β = 0.20) when 
these diff erences are 0.4 SD. Th ese diff erences are called small.
Th e MFI and other HRQoL questionnaires will be analyzed using Repeated Measure-
ment ANOVA. Th e amount of RBC transfusions and the hospital stay will be analyzed 
using two-sided Mann-Whitney U test.
In the Netherlands, the incidence of a RBC transfusion aft er delivery is approximately 
fi ve percent. Th e incidence is, with approximately 200,000 deliveries per year, 10,000 
patients in the Netherlands.
APPENDIX IV
Participating hospitals
At this moment the WOMB study is performed in 10 hospitals in the Netherlands
Participating hospitals
Hospital City
Albert Schweitzer Hospital Dordrecht
Academic Medical Center Amsterdam
Amphia Hospital Breda
Erasmus MC, University Medical Center Rotterdam
Ikazia Hospital Rotterdam
Leiden University Medical Center Leiden
Maxima Medical Center Veldhoven
Medical Center Rijnmond-Zuid Rotterdam
Reinier de Graaf Gasthuis Delft
Sint Franciscus Gasthuis Rotterdam
